(54) **Title: METHOD FOR SOLUTION BASED DIAGNOSIS**

(57) **Abstract:** This invention provides methods for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.

METHOD FOR SOLUTION BASED DIAGNOSIS

This invention relates to methods for performing diagnosis of medically relevant conditions by detecting the levels of relevant markers characteristic for the medically

5   relevant condition and the levels of normalization markers. The methods pertain to characterization of the sample in a solution phase, without relying on morphological cell based information.

BACKGROUND OF THE INVENTION

10   The diagnosis of a large number of medically relevant conditions is currently performed using molecular markers as tools. The molecular tools are generally used as one aspect in a complex examination, taking into account a series of different parameters characterizing the samples to be examined.

In medically relevant analysis, the morphological examination of samples by

15   cytological or histological means is in common use. Such methods based on morphological characterization of cell based samples are applicable for example in analysis of clinical samples such as body fluids, blood, surgical resections, secretions, swabs or lavages.

In screening for cervical cancer, for example, swabs are used for detection of neoplastic lesions of the cervix uteri. In the screening procedure, lesions of different origin

20   have to be distinguished. Causes for lesions may for example be inflammations (due to infectious agents or physical or chemical damage) or preneoplastic and neoplastic changes. In morphological examinations the lesions of different characteristics are sophisticated to distinguish. Thus, for examination of swabs, cytologists and pathologists have to be especially trained and even experienced examiners have a high inter- and intra-observer

25   variance in the assessment of a diagnosis based on cytological specimens. In general the result of the examination is based upon the subjective interpretation of diagnostic criteria by the examining pathologist/cytologist. As a result the rate of false positive and false negative results in the screening tests remains unsatisfying high.

Therefore, in many cases these cytological or histological examination procedures

30   are supported by the use of molecular markers. Such markers are often used in immuno-histochemical staining reactions, or in the course of in-situ hybridization reactions. In the prior art combinations of morphological examinations and immuno-histochemical staining reactions based on marker molecules, characteristic for different medically relevant states of

tissues or cells, may lead to enhanced results. The morphologic examination remains laborious and time consuming and thus expensive, even when supported by the molecular methods, that make the results more reliable. Additionally, the diagnosis on a morphologically cell based level is, even when supported by molecular parameters, subject

5 to individual perception of the morphology by individual examiners. Thus the diagnosis is dependent on the person, that performs the examinations.

Only in very few cases, molecular markers may be used as diagnostic tools without further support by cell based morphological examinations. This is especially the case, if markers are to be detected in an environment, where they do only occur under exactly

10 defined conditions. So the methods for diagnosis of conditions on a molecular level only, without the support of cell based information, are restricted to cases, where there are suitable markers, that are non-ambiguously specific for the condition to be characterized. For example, detection of viral infections may be carried out in solutions of samples, because the markers characteristic for the presence of viruses in tissues do not occur in

15 unaffected human tissues.

The reproducibility of the results of examination can be enhanced by the use of supporting molecular tools. However, the problem with the preservation and preparation of the samples may not be overcome by just additionally using molecular markers.

When using molecular tools in cytological or histological examinations, strict

20 precautions in preserving the samples have to be taken to prevent artefacts and improper results of the tests. This is in part due to the instability of the cell based morphological information and in part to the instability of the molecular markers to be detected during the tests. If the samples are not prepared, transported or stored in the appropriate manner, the cell based information, or even the molecular information may get lost, or may be altered.

25 So the diagnosis may be impossible, or may be prone to artefacts. For example, the interpretation of biopsies or cytological preparations is frequently made difficult or impossible because of damaged (physically or biochemically) cells. Regarding tissue samples or biopsies, the preservation of molecular constituents of the samples, which are subject to a rapid turnover, seems sophisticated due to the time elapsed until penetration of

30 the total sample by appropriate preservatives.

The morphologically supported diagnostic methods performed routinely in the art show two major disadvantages. First, the methods are highly dependent on individual perception of the examiners. Secondly the morphological information is quite sensitive to

decay processes and thus may cause artefacts after preparation of the samples. Both aspects contribute to improper reproducibility of the results.

For improved diagnosis of medically relevant conditions, methods that do not depend on cell based morphological information would be desirable.

5

SUMMARY OF THE INVENTION

The present invention is directed to a method for diagnosing a medically relevant condition of a patient. The method comprises the steps of: obtaining a raw sample containing cells or cell debris from a patient; preparing a sample solution from the raw

10 sample; detecting the levels of one or more relevant markers characteristic for said medically relevant condition in said sample solution; detecting the levels of one or more normalization markers; normalizing the detected level of the relevant markers with respect to said normalization parameters; and diagnosing the medically relevant condition from the normalized levels of said relevant markers within the sample solution. The normalization

15 markers are characteristic for at least one of the following normalization parameters: the presence or absence of a particular cell type among the cells represented within the sample solution, the presence or absence of a particular differentiation pattern in the cells represented within the sample solution, and the presence or absence of particular proliferation properties of the cells represented within the sample solution.

20   In one embodiment of the invention, the medical relevant condition is a cell proliferative disorder, cancer or a precursory lesion.

The present invention is also directed to a test kit for diagnosing a medical relevant condition.

25   BRIEF DESCRIPTION OF THE DRAWINGS

The patent of application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

Figure 1 shows the specific immunohistochemical staining of endocervical and

30 ectocervical epithelial cells in cervical sections. Figure 1A shows a positive reaction detected in columnar epithelium of the endocervix using an antibody directed against cytokeratin 18 (CK18). Figure 1B shows no specific staining in columnar epithelium of the

ectocervix using an antibody directed against cytokeratin 18 (CK18). Figure 1C shows no

specific staining in columnar epithelium of the endocervix using an antibody directed

against cytokeratin 10/13 (CK10/13). Figure 1D shows a strong staining of the squamous

epithelium of the ectocervix using an antibody directed against cytokeratin 10/13

5   (CK10/13).

Figure 2 shows the Western Blot analysis of solubilized samples from cervical

swabs. The numbers 1 to 4 refer to samples (cervical swabs) obtained from individual

patients

Figure 3 shows the Western blot and ELISA analysis to demonstrate sample

10   adequacy.

Samples of four patients with high-grade cervical dysplasias (see Diagnosis) were analysed

using western blot analysis (upper panel of figure). The lower panel of this figure shows the

results of ELISA analysis.

15   **DETAILED DESCRIPTION OF THE INVNETION**

This invention provides methods for improved diagnosis of medically relevant

conditions by solution-based biochemical testing procedures performed in solutions of test

samples. The invention provides a method to substitute the cell based morphological

information contained within the cytological and/or histological data of the test sample by

20   molecular information obtainable from the solution, wherein the original test sample is

dissolved and thus enables for accurate and reproducible assessment of medically relevant

diagnosis from dissolved test samples. The method according to the invention comprises the

steps of determining the levels of one or more markers associated with the condition to be

diagnosed, determining the level of a set of normalization markers suitable to substitute the

25   information related to morphological aspects of the sample, that would have enabled or

supported diagnosis in a cell based test system, comparing and/or combining the data

concerning the levels of said markers and assessing diagnosis of a medically relevant

condition.

The present invention discovers that diagnosis of conditions, which is normally (in

30   cell based diagnostic systems) enabled and/or supported by histological and/or cytological

examination procedures, may be performed in solutions from raw samples containing

various cell types of different characteristics, by a method comprising the steps of obtaining

a raw sample, dissolving the sample in an appropriate solute, detecting the level of one or

5

more markers associated with the condition to be diagnosed and additionally one or more normalization markers within the sample solution, normalizing the data correlating to the markers associated with said condition with respect to the data correlating to the normalization markers and diagnosing the presence or absence of a condition in the sample.

5   The method according to the present invention may for example be applied as a primary screening test in cases, where a cytological, histological or pathological examination is normally performed. Using the present invention one may discriminate, if the condition to be diagnosed may be present in the sample. If the solution based diagnosis gives a negative result concerning a particular condition, a further examination may be
10   omissible. In case of positive results, ascertaining by classically applicable methods may follow. Thus, expensive and time consuming microscopic or other examinations could be avoided by means of an inexpensive rapid primary screening test.

One aspect of the present invention is a method for enhanced diagnosis of medically relevant conditions, wherein the assessment of diagnosis is performed using solutions of
15   lysed raw tissue- or cell-samples. The method for diagnosis disclosed according to the present invention does not rely on morphological parameters but enables for a diagnosis by means of biochemical analysis.

A second aspect of the present invention is a method for characterizing a complex sample in solution by means of molecular markers characteristic for the parameters of
20   interest, thus substituting information, which could otherwise be obtainable from cytological or histological examinations.

A third aspect of the present invention is to provide suitable combinations of markers for the diagnosis of particular conditions of medical relevance in complex samples. The markers for normalization are chosen such that parameters included within the raw
25   sample, that enable or support the diagnosis, which are lost by the dissolution of the sample, may be substituted.

A fourth aspect of the present invention are test kits for performing diagnostic or research studies according to the present invention.

The present invention enables for a rapid and easy assay for diagnosing of
30   conditions in raw samples such as body fluids, swabs, lavages (e.g. bronchio-alveolar lavages, breast ductal lavages, etc.), aspirates (needle-apirates, fine-needle-aspirates) or complex cell- or tissue samples. In general, a problem with raw materials is the presence of a number of different cell-types within the sample and the presence of particular

6

microorganisms and extracellular substances. Thus the raw material contains a mixture of cells and compositions, that is prone to give artefacts as results. The presence of different cell types with different proliferative characteristics, of organisms and substances within the raw sample gives rise to multiple factors, that may contribute to the particular level of a

5 marker molecule. Detecting solely the level of one single molecular marker may thus only lead to a diagnostically useful information, if further (morphological) parameters concerning the raw sample are provided. All morphologic data obtainable from the raw sample are lost due to lysis in solution. Yet there are suitable molecular markers corresponding to particular morphologic or other parameters obtainable by histological,

10 cytological methods.

For example, the information about the single constituents within the raw sample may be classically obtained by microscopic examination. Morphologic inspection gives hints about the differentiation, the localization of cells, as well as about the environment, in which the cells appear. In cytological preparations of cervical-swabs, for example, the

15 particular cells may be identified as epithelial cells and further categorized as e.g. endocervical or ectocervical epithelial cells. Even the presence of non-cervical cells such as endometrial cells may be ascertained easily by microscopic inspection.

According to the present invention, raw materials may directly be dissolved in an appropriate solvent without further preparation or characterization independent of the

20 homogeneous or heterogeneous character of the sample material. Data, which are lost through lysis of the material are contained within the sample solution encoded by the levels of a series of marker molecules and may thus be reconstructed using said molecular data for normalization to the respective morphologic characteristics. This is achieved by employing a suitable set of molecular markers for each of the characteristic parameters needed for

25 unambiguous diagnosis. By detecting a suitable array of markers one may assess the relevant parameters characterizing the raw sample and thus overcome the disadvantage of loss of information through lysis of the sample.

The testing procedure according to the present invention includes detecting the levels of markers characteristic for cell conditions in question and of markers for

30 normalizing the data with respect to parameters characterizing the particular environment in the test sample. The markers suitable for the present invention may be of various origin. The expression pattern of a marker, that is suitable for the detection of conditions in question,

7

may be dependent on the proliferative status of cells, on the differentiation status, on the cell type or on the organism. Examples for appropriate markers are set forth below.

The term diagnosis as used herein generally comprises any kind of assessment of the presence of absence of a medically relevant condition. Diagnosis thus comprises processes
5   such as screening for the predisposition for a medically relevant condition, screening for the precursor of a medically relevant condition, screening for a medically relevant condition, clinical or pathological diagnosis of a medically relevant condition, etc.. Diagnosis of medically relevant conditions as used herein may comprise examination of any condition, that is detectable on a cytological, histological, biochemical or molecular biological level,
10 that may be useful in respect to the human health and/or body. Such examinations may comprise e.g. medically diagnostic methods and research studies in life sciences. In one embodiment of the invention, the method is used for diagnosis of medically relevant conditions such as e.g. diseases. Such diseases may for example comprise disorders characterized by non-wild type proliferation of cells or tissues.

15   In one embodiment, the diagnosis pertains to diagnosis of cancers and their precursory stages, to monitoring of the disease course in cancers, to assessment of prognosis in cancers and to detection of disseminated tumor cells e.g. in the course of minimal residual disease diagnosis. The method according to the present invention may for example be used in the course of clinical or pathological diagnosis of cancers and their precursory
20 stages or in routine screening tests as performed for particular cancers such as for example for examination of swabs e.g. in screening tests for cervical lesions, of bronchial lavages for lung cancer or of stool for lesions of the gastrointestinal tract, e.g. colorectal lesions.

The method according to the present invention is applicable to all kinds of medically relevant conditions.

25   Medically relevant conditions as used according to the present invention may for example be compositions of tissues, body fluids, secretions, washes or swabs. Such conditions may for example comprise the cellular composition of body fluids, such as the composition of blood, the composition of liquor or the composition of semen. In this context the compositions shall be for example the presence or absence of particular cell
30 types (e.g. pathogens, such as, viruses etc., preneoplastic, neoplastic and/or dysplastic cells etc.), the presence or absence of differentiation patterns of particular cell types, the total number of a particular cell types (e.g. erythrocytes, leucocytes, sperm, etc.), the total

8

number of all cells of any cell types or the fraction of cells of particular other characteristics present or absent in the sample.

Furthermore, medically relevant conditions may also comprise disorders related to cells, or tissues. The conditions to be diagnosed may comprise parameters related to cells in cytological or histological tissue samples. The conditions may comprise a differentiation pattern of cells in a tissue sample, such as surgical resection samples, biopsies, swabs, lavages etc. Such conditions may comprise e.g. congenital disorders, inflammatory disorders, mechanical disorders, traumatic disorders, vascular disorders, degenerative disorders, growth disorders, benign neoplasms, malignant neoplasms. Another aspect of the conditions according to the present invention may comprise conditions characterized by the presence or absence of proliferative characteristics. Conditions characterized by the presence or absence of proliferative characteristics may be for example cell proliferative disorders.

Cell proliferative disorders according to the present invention comprise diseases characterized by abnormal growth properties of cells or tissues compared to the growth properties of normal control cells or tissues. The growth of the cells or tissues may be for example abnormally accelerated, decelerated or may be regulated abnormally. Abnormal regulation as used above may comprise any form of presence or absence of non wild-type responses of the cells or tissues to naturally occurring growth regulating influences. The abnormalities in growth of the cells or tissues may be for example neoplastic or hyperplastic.

In one embodiment, the cell proliferative disorders are tumors. Tumors may comprise tumors of the head and the neck, tumors of the respiratory tract, tumors of the anogenital tract, tumors of the gastrointestinal tract, tumors of the urinary system, tumors of the reproductive system, tumors of the endocrine system, tumors of the central and peripheral nervous system, tumors of the skin and its appendages, tumors of the soft tissues and bones, tumors of the lymphopoietic and hematopoietic system, etc. Tumors may comprise for example neoplasms such as benign and malignant tumors, carcinomas, sarcomas, leukemias, lymphomas or dysplasias. In a particular embodiment, the tumor is for example cancer of the head and the neck, cancer of the respiratory tract, cancer of the anogenital tract, cancer of the gastrointestinal tract, cancer of the skin and its appendages, cancer of the central and peripheral nervous system, cancer of the urinary system, cancer of

the reproductive system, cancer of the endocrine system, cancer of the soft tissues and bone, cancer of the hematopoietic and lymphopoietic system.

Tumors of the anogenital tract may comprise cancer of the perineal, the perinanal and the scrotal skin, cervical cancer, cancer of the vulva, cancer of the vagina, caner of the
5   penis, cancer of the anus, etc. Cervical cancer may comprise squamous lesions, glandular lesions or other epithelial tumors. Squamous lesions comprise, e.g., cervical intraepithelial neoplasias (mild, moderate and severe dysplasia), carcinoma in-situ, squamous cell carcinoma (e.g., keratinizing, nonkeratinizing, verrucous, warty, papillary, lymphoepithelioma-like). Glandular lesions may comprise atypical hyperplasias,
10 adenocarcinoma in-situ, andenocarcinoma (such as, e.g., mucinous, endometrioid, clear cell, adenoma malignum, papillary, serous or mesonephric adenocarcinoma). Other epithelial tumors may comprise adenosquamous carcinoma, glassy cell carcinoma, adenoid cystic carcinoma, adenoid basal carcinoma, carcinoid tumor, small cell carcinoma and undifferentiated carcinoma. For more detailed information, confer "Kurman, R., Norris, H.,
15 *et al., Tumors of the Cervix, Vagina, and Vulva, Atlas of Tumor Pathology*, 1992, AFIP," the contents of which shall be incorporated herein by reference.

Gastrointestinal tumors may comprise colon cancer, cancer of the colon ascendens, of the colon descendens, of the colon transversum, of the sigmoidum, of the rectum, cancer of the small intestine, cancer of the jejunum, cancer of the duodenum, gastric cancer,
20 oesophageal cancer, liver cancer, cancer of the bile, cancer of the biliary system, pancreatic cancer, etc. A comprehensive overview over gastrointestinal lesions is given in "Hamilton Sr, Aaltonen LA (Eds.): World Health Organization Classification of Tumours, *Pathology and Genetics of Tumors of the Digestive System*, IARC Press: Lyon 2000," which shall be incorporated herein by reference.

25   Tumors of the respiratory tract may comprise any malignant condition of the respiratory tract such as, e.g., cancer of the lung, the alveoles, the bronchioles, the bronchial tree and the broncus, the nasopharyngeal space, the oral cavity, the pharynx, the nasal cavity and the paranasal sinus. Lung cancer such as small cell lung cancer, non-small cell lung cancer, squamous cell lung carcinoma, small cell lung carcinoma, adenocarcinoma of the
30 lung, large cell lung carcinoma, adeno-squamous lung carcinoma, carcinoid tumor of the lung, broncheal gland tumor or (malignant) mesothelioma. An overview over tumors of the respiratory tract may be found in Colby TV, *et al.: Tumors of the Lower RespiratoryTract,*

Atlas of Tumor Pathology, Third Series, Fascicle 13, AFIP: Washington 1995," which shall
be incorporated herein by reference.

Tumors of the urinary system may comprise bladder cancer, cancer of the kidney,
renal pelvis, cancer of the ureters and cancer of the urethra, etc. Tumors of the reproductive
5   system may comprise cancer and precursory stages thereof of the ovary, the uterus, the
testis, the prostate, the epididymis, etc.

In all cases, the methods according to the present invention also apply to precursor
stages of the lesions, tumors or cancers.

In one embodiment, the method according to the present invention pertains to the
10 detection of disseminated tumor cells or metastases.

In one embodiment of the invention, the carcinoma is e.g. cervical cancer, colon
cancer, gastric cancer, breast cancer, bladder cancer, lung cancer, cancer of the oral cavity
etc.

The present invention provides a number of robust, fast and easy ways to preserve
15 molecular properties of samples, whereby the morphological information of samples is lost.
Samples may be e.g. prepared in a reproducible and easy to store and transport form by
dissolving the cellular components of the raw sample in a suitable solvent immediately after
or even during obtaining the sample. Body fluids may directly be transferred from the body
of an individual to a solution containing suitable detergents and preservative substances.
20 Furthermore, tissue samples may immediately be transferred to denaturing lysis conditions
(eventually supported by physical forces) and be thus preserved. Using appropriate
ingredients in the solvent, the molecular components of the original sample may be
preserved, and no degradation may occur. The degradation by enzymatic activities may, for
example, be minimized by the use of enzyme inhibitors. Thus, a solution of test samples
25 may easily represent the molecular properties of a test sample at the time of dissolution,
without requiring additional preservative precautions.

Raw samples may comprise clinical samples, such as e.g. secretions, swabs, lavages,
body fluids, blood, urine, semen, stool, bile, liquor, bone marrow, biopsies, cell- and tissue-
samples. Biopsies as used in the context of the present invention may comprise e.g.
30 resection samples of tumors, tissue samples prepared by endoscopic means or punch- or
needle- biopsies of organs. Furthermore, any sample potentially containing the marker
molecules to be detected may be a sample according to the present invention. In one
embodiment of the invention, the sample comprises cervical swabs, bronchial lavages, stool

etc. Raw sample as used in the context of the present invention may comprise fixed or preserved cell or tissue samples. E.g. cells preserved in suitable solutions (alcohols etc.) or fixed tissue samples may be used as raw samples in the methods according to the present invention.

5   A raw sample according to the method of the present invention includes any sample comprising cells or cell debris. The cells may for example be prokaryotic or eukaryotic cells.

When the present invention is applied for the detection of infectious diseases, the cells to be determined may be cells of microorganisms such as chlamydia, *E. coli*, candida, etc.

10   According to the present invention, all or part of the molecular components of the raw samples are solubilized in a suitable lysis buffer comprising e.g. solvents. Such solvents may for example be aqueous solutions of chaotropic agents such as e.g. urea, GuaSCN, Formamid, of detergents such as anionic detergents (e.g. SDS, N-lauryl sarcosine, sodium deoxycholate, alkyl-aryl sulphonates, long chain (fatty) alcohol sulphates, olefine sulphates

15 and sulphonates, alpha olefine sulphates and sulphonates, sulphated monoglycerides, sulphated ethers, sulphosuccinates, alkane sulphonates, phosphate esters, alkyl isethionates, sucrose esters), cationic detergents (e.g. cetyl trimethylammonium chloride), non-ionic detergents (e.g. Tween 20, Nonidet P-40, Triton X-100, NP-40, Igepal CA-630, N-Octyl-Glucosid) or amphoteric detergents (e.g CHAPS, 3-Dodecyl-dimethylammonio-propane-1-

20 sulfonate, Lauryldimethylamine oxide) and/or of alkali hydroxides such as e.g. NaOH or KOH. The solvent is designed, so that cells, cell debris, nucleic acids, polypeptides, lipids and other biomolecules potentially present in the raw sample are dissolved. The solution for dissolving the raw samples according to the present invention may furthermore comprise one or more agents that prevent the degradation of components within the raw samples.

25 Such components may for example comprise enzyme inhibitors such as proteinase inhibitors, RNAse inhibitors, DNAse inhibitors etc. In one embodiment of the present invention the sample is lysed directly in the form it is obtainable from the test-individuals. In another embodiment of the present invention the sample may be further purified before being lysed. Such purification procedures may for example comprise washing away of

30 contaminants such as mucus or the like, separation or concentration of cellular components, preserving and transporting of the cells. Thus the cellular components of the raw samples are included in a single sample solution.

The preparation of a sample for use in a method as disclosed herein may also comprise several steps of further preparations of the sample, such as separation of insoluble components, isolation of polypeptides or nucleic acids, preparation of solid phase fixed peptides or nucleic acids or preparation of beads, membranes or slides to which the

5 molecules to be determined are coupled covalently or non-covalently.

According to the present invention, the detection of the marker molecules is performed directly from this solution. The detection may be carried out in solution or using reagents fixed to a solid phase. In certain embodiments of the present invention the detection of the marker molecules is performed from a solution of dissolved body samples.

10 Therefore detection may be carried out in solution or using reagents fixed to a solid phase. A solid phase as used in the context of the present invention may comprise various embodiments of solid substances such as planar surfaces, particles (including micro-, nano-particles or even smaller particles). In certain embodiments particles may be provided as beads, colloids or the like. The fixation of reagents to the solid phase in a test kit or an in-

15 vitro diagnostic device may be effected via direct fixation or via indirect fixation. Direct fixation may e.g. be effected by covalent or non-covalent binding or association to surfaces. Indirect fixation may be effected through binding of the reagents (e.g. antibodies, probes etc.) to agents which themselves are directly fixed to solid phases. Such agents may comprise antibodies or other binding agents like Streptavidin, biotin or the like. The

20 detection of one or more molecular markers may be performed in a single reaction mixture or in two or more separate reaction mixtures. The detection reactions for several marker molecules may for example be performed simultaneously in multi-well reaction vessels or as the case may be on one single or two or more separate test strips. The markers characteristic for the cell proliferative disorders may be detected using reagents that

25 specifically recognise these molecules. Simultaneously the normalization markers may be detected using reagents, that specifically recognize them. The detection reaction for each class of markers may comprise one or more further reactions with detecting agents either recognizing the initial marker molecules or preferably recognizing the prior molecules (e.g. primary antibodies) used to recognize the initial markers. The detection reaction further may

30 comprise a reporter reaction indicating the level of the markers characteristic for cell proliferative disorders or the normalization markers.

The terms "marker" or "marker molecule" in all their grammatical forms as used in the context of the present invention refers to nucleic acid as well as polypeptide molecules.

13

Marker or marker molecule thus comprises e.g. RNA (mRNA, hnRNA, etc.), DNA (cDNA, genomic DNA, etc.), proteins, polypeptides, proteoglycans, glycoproteins and the respective fragments of these molecules. The term "relevant marker" shall refer to marker molecules characteristic for a medically relevant condition. The term normalization marker shall refer

5 to marker molecules used for normalization purposes.

A level of a marker molecule as used herein refers to a semiquantitave as well as a quantitative value regarding the amount of the respective marker present in a sample. A quantitative value may e.g. be represented in terms of a concentration. A semiquantitative value may be expressed in terms of a scale of levels e.g. undetectable levels, low levels,

10 intermediate levels, high levels or any other suitable mode. The level of a marker may also be represented in terms of a dependent parameter such as the intensity of a signal generated in an assay format in response to the presence of a marker molecule.

A probe for the detection of the marker molecules as used in the context of the present invention shall be any molecule, that specifically binds to said marker molecules.

15 The probe may for example be an antigen binding agent such as antibodies (monoclonal or polyclonal), antibody fragments or artificial molecules comprising antigen binding epitopes, DNA or RNA binding molecules such as proteins or nucleic acids. Nucleic acids binding to other nucleic acids may for example be peptide nucleic acids (PNAs) or oligonucleotides (RNA, DNA, PNA, artificial nucleic acids, etc.) for detection purposes or primers.

20   A molecule is said to recognize another molecules if it specifically interacts with that molecule. Specific interaction may for example be specific binding to or of the other molecule.

The reporter reaction may be for example a reaction producing a colored compound. In one embodiment of the present invention the reporter substances correlated to the

25 particular markers develop different colors. In another embodiment, the normalization marker specific reporter may be a molecule quenching the signal produced by the reporter molecule specific for the marker, characteristic for the medically relevant condition, in dependence on the level of the normalization marker present in the sample. In yet another embodiment the reporter reactions may produce fluorescent dyes with differing wavelength

30 characteristics. In a further embodiment of the present invention the reporter reaction may comprise light emitting reactions with different wavelength characteristics for the reporter substances specific for either marker to be detected. In another embodiment of the present invention the reporter reaction may comprise the emission of radioactive radiation and

additional methods for visualizing or quantifying the radiation. In one embodiment, the different marker molecules may be recognized by agents, that bear radio-nuclides emitting radiation with different energetic properties, so that the signals referring to marker molecules could be distinguished.

5   Applicable formats for the detection reaction according to the present invention may be blotting techniques, such as Western-Blot, Southern-blot, Northern-blot. The blotting techniques are known to those of ordinary skill in the art and may be performed for example as electro-blots, semidry-blots, vacuum-blots or dot-blots. Furthermore immunological methods for detection of molecules may be applied, such as for example

10   immunoprecipitation or immunological assays, such as EIA, ELISA, RIA, lateral flow assays, flow through assays, immunochromatographic strips, etc. Immunoassays for use in the invention may comprise competitive as well as non-competitive immunoassays.

        In certain embodiments of the invention immunochemical or nucleic acid based testing may be performed using a testing device for clinical laboratories. Such testing device

15   may comprise any device suitable for immunochemical or nucleic acid based testing including any format such as e.g. Point of care testing devices as well as bench top or laboratory devices. The devices may be e.g. provided as open or closed platform systems. The system may be based on any suitable methodology such as e.g. employing microtiter plates, multiwell plates, flow through or lateral flow systems, microchip or array based

20   systems or bead or membrane based systems. The detection methods employed may comprise any methods known to those of skill in the art useful for immunochemical or nucleic acids based detection reactions. Such detection systems may be e.g. luminescence systems (electroluminescence, bioluminescence, photoluminescence, radioluminescence, chemiluminescence, electrochemoluminescence), fluorescence based systems, conductivity

25   based detection systems, radiation (light, UV, X-ray, gamma etc.) or any other known method.

        The method for detection of the level of the marker molecules in one embodiment of the present invention is any method, which is suited to detect even very small amounts of specific molecules in biological samples. Furthermore any method for detection of the

30   marker molecules irrespective of the sensitivity may be applied. The detection reaction according to the present invention may comprise for example detection reactions on the level of nucleic acids and/or detection reactions on the level of polypeptides. In one embodiment of the invention, the detection of the marker molecules may comprise the

detection of particular splicing variants. In another embodiment of the present invention, the detection method may comprise the detection of modifications of marker molecules such as phosphorylation or glycosylation etc of polypeptides or the methylation of nucleic acid molecules in samples.

5   In one embodiment of the invention, the detection of the level of marker molecules is carried out by detection of the level of nucleic acids coding for the marker molecules or fragments thereof present in the sample. The means for detection of nucleic acid molecules are known to those skilled in the art. The procedure for the detection of nucleic acids can for example be carried out by a binding reaction of the molecule to be detected to

10   complementary nucleic acid probes, proteins with binding specificity for the nucleic acids or any other entities specifically recognizing and binding to said nucleic acids. This method can be performed as well in vitro as directly in-situ for example in the course of a detecting staining reaction. Another way of detecting the marker molecules in a sample on the level of nucleic acids performed in the method according to the present invention is an amplification

15   reaction of nucleic acids, which can be carried out in a quantitative manner such as for example the polymerase chain reaction. In one embodiment of the present invention e.g. real time RT PCR may be used to quantify the level of marker RNA in samples of cell proliferative disorders.

         In another embodiment of the invention, the detection of the level of marker

20   molecules is carried out by determining the level of expression of a protein. The determination of the marker molecules on the protein level may for example be carried out in a reaction comprising a binding agent specific for the detection of the marker molecules. These binding agents may comprise for example antibodies and antigen-binding fragments, bifunctional hybrid antibodies, peptidomimetics containing minimal antigen-binding

25   epitopes etc. The binding agents may be used in many different detection techniques for example in western-blot, ELISA, RIA, EIA, flow through assay, lateral flow assay, latex-agglutination, immunochromatographic strips or immuno-precipitation. Generally binding agent based detection may be carried out as well in vitro as directly in situ for example in the course of an immunocytochemical staining reaction. Any other method suitable for

30   determining the amount of particular polypeptides in solutions of biological samples can be used according to the present invention.

         Methods for the detection of the modified states of nucleic acid molecules and/or polypeptides are known to those of ordinary skill in the art.

16

Methods for detection of methylation of nucleic acids are known to those of skill in the art and may comprise for example methods employing chemical pre-treatment of nucleic acids with e.g. sodium bisulphite, permanganate or hydrazine, and subsequent detection of the modification by means of specific restriction endonucleases or by means of

5   specific probes e.g. in the course of an amplification reaction. The detection of methylation may furthermore be performed using methylation specific restriction endonucleases. Methods for the detection of methylation states in nucleic acids are e.g. disclosed in patent application EP02010272.9, US5856094, WO0031294, US6331393 etc. The cited documents are incorporated herein by reference.

10   Detection of modified states of polypeptides may for example comprise binding agents specifically recognizing modified or unmodified states of polypeptides. Alternatively enzymes such as phosphatases or glycosylases may be used to remove modifications in molecules. The presence or absence of modifications can thus be detected by determination of mass or charge of the molecules by means of electrophoresis, chromatography, mass

15   spectrometry etc. prior and subsequent to the incubation with a respective enzyme.

In a further embodiment of the present invention, the detection of a series of marker molecules is carried out on the level of polypeptides and simultaneously the detection of a further series of marker molecules and/or of all or some of the same marker molecules is carried out on the level of nucleic acids.

20   Markers associated with medically relevant cellular conditions may e.g. be molecules which influence and/or reflect the proliferation and/or differentiation characteristics of cells and/or tissues. Such molecules may comprise for example cell cycle regulatory proteins, proteins associated with the DNA replication, transmembrane proteins, receptor proteins, signal transducing proteins, calcium binding proteins, proteins containing

25   DNA-binding domains, metalloproteinases, kinases, kinase inhibitors, chaperones, embryogenesis proteins, heat shock proteins or enzymes which modify other proteins posttranslationally thus regulating their activity, or nucleic acids coding for the named proteins. Also mRNA coding for the named proteins may be marker molecules useful according to the present invention. In one embodiment the marker associated with the cell

30   proliferative disorder may be for example uniquely expressed in cells affected by the disorder, may be not expressed in said cells or may be overexpressed in said cells.

Marker molecules for use according to the present invention may comprise one or more markers chosen from p13.5, p14, p15, p16 (also referred to p16^{INK4a}), p19, p21, p27,

17

p53, pRb, p14ARF, cyclin A, cyclin B, cyclin E, MDM-2, MCM2, MCM5, MCM6, CDC2, CDC6, Id1, osteopontine, GRP, renal dipeptidase, her2/neu, TGFßII receptor, HPV associated markers e.g. derived from HPV genes L1, L2, E1, E2, E4, E5, E6 or E7, etc. A selection of markers useful in one embodiment of the present invention for the detection of

5   medically relevant conditions is shown below in Table 1.

        In one embodiment the marker for a medically relevant condition may be a marker for tumors (tumor markers). The marker molecules characteristic for tumors may e.g. be proteins, that are expressed in a non-wild type manner in tumors compared to normal control tissue. Non-wild type expression as used herein may comprise increased or

10   decreased levels of expression or lack of expression or expression of non-wild type forms of the respective molecules. Expression of non-wild type forms of a protein may comprise expression of mutated forms of proteins, arising by insertion, deletion, substitution, or frameshift mutations or any other known types of mutations in proteins or nucleic acids. In all cases of the expression of non-wild type proteins or non-wild type levels of proteins the

15   proteins, polypeptides or fragments thereof or nucleic acids encoding these proteins or polypeptides or fragments of these nucleic acids may be used as molecular markers associated with tumors and may thus be understood under the term "tumor marker" as used in the context of the present invention. Proteins that show non-wild type expression in association with tumors are disclosed for example in the documents WO9904265A2,

20   WO0149716A2, WO0055633A2 and WO0142792A2, which shall be incorporated by reference herein.

        In one embodiment of the invention, the marker characteristic for the medically relevant condition may be a cell cycle regulatory protein such as for example a cyclin, a cyclin dependent kinase or a cyclin dependent kinase inhibitor. In a further embodiment of

25   the invention the marker characteristic for the medically relevant condition may be a marker associated with a transient or a persistent viral infection. The viral infection may comprise an infection by a human papilloma virus (HPV) such as high risk or low risk HPV. The high risk HPV may comprise HPV subtypes such as e.g. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56 and 58. The markers for HPV infection may e.g. comprise HPV expression products of

30   HPV genes L1, L2, E2, E4, E5, E6 or E7. In a third embodiment of the invention a marker characteristic for a viral infection may be used in combination with any other marker for a medically relevant condition such as e.g. in combination with a cell cycle regulatory protein. Combinations of marker molecules, which may be of special interest with respect to

18

HPV association are e.g. disclosed in WO0208764 which document shall be incorporated herein by reference.

In one embodiment, cell cycle regulatory proteins for use in combination with HPV markers may for example be chosen from a group comprising pRb, p53, p14 ARF, cyclin

5 dependent kinase inhibitors. In one special embodiment for example p16^{INK4a} may be used in combination with markers for HPV infection (e.g. L1, L2, E2, E4, E5, E6 or E7).

It must be understood, that as the case may be markers useful as markers for medically relevant conditions in certain embodiments may serve as markers for normalization in certain other embodiments and vice versa. However in each single

10 embodiment a marker can only serve either as marker for the medically relevant condition or as marker for normalization. For example Ki67 as a marker for cell proliferation may be useful as normalization marker in certain embodiments (e.g. in combination with p16, p14ARF, claudin-1 or others as markers for medically relevant condition); in other embodiments Ki67 may serve as marker for medically relevant condition (e.g. as marker for

15 cervical dysplasia or other dysplastic diseases) in combination with suitable normalization markers (e.g. cytokeratins, catenins or others). Various other markers may likewise serve either as marker for medically relevant conditions or for normalization depending on the particular embodiment of application.

Normalization markers according to the present invention may comprise for example

20 housekeeping genes, such as actin, gapdh, histone proteins, phospholipase, ß2-microglobulin, proteins associated with active cell proliferation such as e.g. Ki67, PCNA or statin, or proteins characteristic for particular cell types such as for example CK20 in epithelial cells or any cell specific cell-surface antigens. In addition, carbohydrate structures present on glycoproteins, proteoglycans, lectin receptors such as the concanavalin A

25 receptor, mucins and enzymes which are involved in the biosynthesis of these molecules such as GalNac transferases and oligosaccharyltransferases might also serve as normalization markers. The type of marker protein has to be chosen according to the information, which shall be provided by the marker. Principally the markers useful for particular medically relevant conditions may under certain circumstances be useful as

30 normalization markers. A selection of markers useful in performing the methods according to the present invention are given in Table 1.

As well concerning markers for medically relevant conditions as well as concerning normalization markers modified states of molecules (such as polypeptides and nucleic

19

acids) may be used as markers in the method according to the present invention. For example phosphorylated, glycosylated or otherwise modified polypeptides or methylated nucleic acids may be addressed as markers in the method according to the present invention.

Normalization as used according to the present invention shall comprise any method

5 suitable for relating the detected levels of markers to parameters valuable for the assessment of the diagnosis. One aspect of this normalization may be a reconstruction of the relevant cytological and histological information contained within the raw sample by means of suitable molecular markers detectable in the sample solutions. Normalization may comprise for example the detection of the total number of cells present in the sample, of the presence

10 or absence of a particular cell types in a sample, of the presence or absence of an organism or of cells of an organism in a sample, of the number of cells of a particular cell type or organism present in the sample, of the proliferative characteristics of cells present in the sample or of the differentiation pattern of the cells present in the sample.

In certain embodiments normalization may also comprise proving the adequacy of

15 the test, wherein as the case may be inadequate test results may be discarded or classified as invalid. Therefore normalization as used in the context of the present invention may comprise qualitative or semi-quantitative methods for normalization. In certain embodiments semi-quantitative normalization may comprise determining a threshold value for a normalization marker. In one embodiment semi-quantitative normalization may be

20 applied e.g. as follows: the level determined for the relevant marker may be regarded as a valid test result only if the level of the normalization marker exceeds a defined threshold value; in case the threshold value is not reached the test result for the relevant marker is regarded as invalid; diagnosis may not be assessed on the basis of the test. In other embodiments a threshold may be set that may not be exceeded. In certain embodiments

25 qualitative normalization may be performed with respect to the presence or absence of a normalization marker. In those cases e.g. the value determined for the relevant marker is compared to the presence or absence of a normalization marker. As predefined the value is valid only in case the normalization parameter (presence or absence of a detectable level of the normalization marker) is met.

30   **Table 1**

marker for	cell type	antigen	Antibody	supplier	Literature
cell type	epithelial cells	human epithelial cell surface glycoprotein	HEA125 IgG1 (W, IHC, ICC, IF)	Research Diagnostics Inc.	Kommoss et al., Hum Pathol. 2000 Sep;31(9):1055-61

		Human epithelial proliferation 40 kD protein (from LoVo)	AUA-1 IgG1 (Elisa)	Research Diagnostics Inc.	Gottschalk et al, Pathol Res Pract. 1992 Feb;188(1-2):182-90
		Human epithelial antigen (34+39 kD)	Ber-EP4, IgG1 (IHC, Elisa)	Dako	Latza U et al., J Clin Pathol. 1990 Mar;43(3):213-9
		Human epithelial proliferating antigen (40 kD)	AUA-1 (Elisa, W, IHC)	Research Diagnostics Inc.	Epenetos, A et al., Lancet. 1982 Nov 6;2(8306):1004-6
	endocervix columnar cells	Cytokeratin 18 (45 kD)	RGE 53, IgG1 (W, IHC, IF)	Research Diagnostics Inc.	Smedts F et al., Am J Pathol. 1990 Mar;136(3):657-68
		Cytokeratin 18 (45 kD	RCK 106 (W, IHF, IHC)	Research Diagnostics Inc	Smedts F et al., Am J Pathol. 1990 Mar;136(3):657-68
		Cytokeratin 8 (52.5 kD)	CAM 5.2 (W, IHC)	BD PharMingen	Smedts F et al., Am J Pathol. 1990 Mar;136(3):657-68
	Endocervical columnar cells	Mucin Antigens (Tn, STn, MUC1, MUC2	DF3	Centocor	Tashiro et al., Hum Pathol. 1994 Apr;25(4):364-72
	Endocervic Columnar cells	Concanavalin A receptor			Herckenrode et al., Br J Cancer. 1988 Mar;57(3):293-4 ; Koch et al., Br J Cancer. 1986 Jan;53(1):13-22
	Endocervix	GalNacTransferase Oligosaccharyltransferase			Chilton et l., Endocrinology. 1988 Sep;123(3):1237-44
	Endocervic/E ctocervix	Lectins (ConA, WGA, PNA, UEA I, DBA, SBA, SNA			Di Loretto et al., Basic Appl Histochem. 1987;31(2):143-52; Versura et al., Basic Appl Histochem. 1988;32(2):219-27
	ectocervix squamous cells	Plakophilin (80.5 kD	PP1-5C2, IgG1 (W, Elisa, IHC, IF)	Research Diagnostics Inc.	Heid, HW, Differentiation. 1994 Dec;58(2):113-31
	endometrial cells	Vimentin	VIM 3B4, IgG1, (W, ELISA, IF, IHC)	Research Diagnostics Inc.	Smedts F et al., Am J Pathol. 1990 Mar;136(3):657-68

	Erythrocytes	Haemoglobin	RDI-CBL63 , IgM (RIA,EIA)	Research Diagnostics Inc.	Smith et al., J. Histochem. Cytochem. 1998
inflammation	neutrophilic granulocytes NK-cells Macrophages	CD16(NK, Macro, Gran)	DJ130-c, IgG1 (IHC)	DIANOVA	Grundhoever D and Patterson BK, Cytometry 2001;46:340-344
		CD56(NK)	clone Ki-M6		Hermann et al., J. Clin. Immunol. 1990
		CD68(Macro)	(antiCD68)		Cavayal et al., Eur. J. Immunol: 1998(6)1991-2002 (CD56)
	B-cells	CD19 (CD20)	clone AE 1, FACS	DIANOVA	Harrada et al., Blood 1993 ;81 :2658-63 (CD19) Mason et al., Am J. Pathol1990 ;136 :1215-22(CD20)
	T-cells	CD3 (panTcell) (CD4); (CD8)	clone CRIS-7 (antiCD3); IF, IHC,WB	DIANOVA	Jones et al., J Immunol 1993 ; 150 :5429-35
tumor cells	dysplastic and neoplastic cervical cells	p16^{INK4a}	E6H4, D7D7	MTM	Klaes R., et. al. Int J Cancer. 2001 Apr 15;92(2):276-84
	different cancer cell types	P53 (mutations)			Mendoza-Rodriguez CA, et al., Rev Invest Clin 2001 May-Jun;53(3):266-73
	adeno-carcinoma cells	CEA			Mistretta et al., Experientia. 1974 Oct 15;30(10):1209-10; Rogers et al., Eur J Cancer Clin Oncol. 1984 Oct;20(10):1279-86
	bladder cancer cells	NMP22, BTA			van der Poel HG et al., Curr Opin Urol,11,503-509, 2001
	lung cancer cells	PreproGRP			Hamid et al., Cancer, 63, 266-271, 1989, Pagani et al., Int. J. Cancer 47, 371-375, 1991
proliferation	all proliferating cells	PCNA Ki67	Pc10, IgG2a	Zymed	Waseem NH, Lane DP, J Cell Sci 1990:96:121 (PCNA) Cattoretti et al., J Pathol 1992: 168:357-63(Ki67)
infectious agent	HPV 16	E6	BF 7, IgG1 (IHC and in diagnostic kits for cervical swabs)	Research Diagnostics Inc.	Iftner et al., J Virol. 1988 Oct;62(10):3655-61
		L1	CamVir-1, IgG2a (IP, W, IF, IHC)	Research Diagnostics Inc.	Browne L et al., J Gen Virol. 1988 Jun;69 (Pt 6):1263-73
	HPV 18	L1	RDI-HPV18-5A3, IgG1 (W, IHC)	Research Diagnostics Inc.	Iftner et al., J Virol. 1988 Oct;62(10):3655-61
	HPV 6,11,18			RDI-HPVX-4C4	Research Diagnostics Inc.	Iftner et al., J Virol. 1988 Oct;62(10):3655-61 Gouillou et al., Am. J. Surg. Pathol., 1991

According to the present invention the normalization may comprise the

determination of the presence of a number of (human) cells in question in a sample. This is

5   a crucial aspect of the invention. In particular, embodiments false (especially false negative)

22

results of tests can only be avoided, if the testing procedure verifies, that the test sample

contains the materials (e.g. cells, tissues organisms etc.), that are necessary for performing

the particular test. In various tests this will comprise ensuring, that the sample contains

cells. In a wide range of embodiments of the invention the verification of the adequacy of

5   the sample will not just comprise ensuring of the presence of cells, but will include the

detection of the presence of cells of a distinct origin or of a special cell type.

Thus normalization may also comprise the determination of cells of particular origin

such as e.g. cells from a particular organ or of a particular histological localization such as

for example the detection of cells of distinct regions of epithelia, or of cells of connective

10 tissue, cells originating from the basal lamina of a tissue or of cells of a heterologous origin,

such as metastatic cells. This may be necessary in particular cases, because there might be

cells, that under certain circumstances do express a marker, which might be used for the

detection of a medically relevant condition, such as e.g. neoplasia or dysplasia, under

certain normal conditions. Normalization as used according to the present invention may

15 comprise the detection of the presence or absence and/or the level of any cell-types, that

may possibly contribute to the total level of a particular marker selected to diagnose a

medically relevant condition.

In one embodiment, the method may be applied for the detection of cervical lesions.

Cervical lesion may comprise any kind of cervical dyplasia such as cervical cancers as

20 defined above and its precursory stages. Markers and combinations thereof useful for this

detection purpose are for example disclosed in WO0208764 and EP1217377, which

documents shall be incorporated herein by reference. In this embodiment the test may be

performed using any suitable sample of cervical origin. The sample may for example

comprise biopsies or microbiopsies of the cervix or swabs taken from the cervical region.

25 Cervical swabs as used herein are samples that may for example be obtained using a

suitable device such as a brush, a tampon, a spatula or the like, which is contacted with the

uterine cervix during the sampling procedure. The sampling device may be any suitable

device, which may be used in conventional testing performed by a physician or a self

sampling device.

30   Promising molecular markers for enhancing the evaluation of cervical swabs are e.g.

$p16^{INK4a}$, p14ARF, cyclin E, cyclin A, cyclin B, MN, her2/neu, mdm-2, bcl-2, EGF-

Receptor, mcm-2, mcm-5, claudin-1, Markers indicative for Human papilloma virus

infection, pRb, p53 etc. which might be used to detect dysplastic and neoplastic cells.

Normalization according to the present invention for the purpose of analysis of cervical

swabs may comprise the detection of the presence of human cells at all, the detection of

cells of the cervical epithelium, the detection of the presence of endocervical as well as

ectocervical cells and the detection of cells of endometrial origin. The endocervical

5   epithelium is a glandular columnar epithelium. Cells originating from the endocervix may

thus be identified by markers, that are selectively expressed by columnar epithelial cells or

by cells in glandular epithelia. The ectocervical epithelium is a squamous epithelium.

Identification of ectocervical cells thus may be achieved by detection of markers

characteristic for squamous epithelial cells. In certain embodiments the detection of

10   epithelial cells (comprising squamous as well as columnar epithelia) may be sufficient. In

other embodiments the differentiation of especially endocervical cells may be crucial. It is a

crucial step to ensure the presence of ecto- and endocervical cells within the sample to

ensure, that the specimen was taken at the cervical transformation zone, where most

dysplasias and neoplasias arise. If there are no such cells, the sample is not adequate for the

15   testing procedure, for it is prone to give false negative results. As $p16^{INK4a}$ may be expressed

in normal endometrial cells normalization of the $p16^{INK4a}$ expression level in regard to the

number of endometrial cells might be necessary.

To enable for reliable diagnosis the normalization furthermore may comprise the

detection of the presence or absence of the named cellular components within the sample,

20   and additionally the detection of the total level of a particular cell type or of the fraction,

that a particular cell type contributes to the total number of cells within the sample.

Thus, in one embodiment the detected level of the $p16^{INK4a}$ protein may be

normalized to the cytological conditions represented by the particular sample, so that one

may state, if the detected level of the $p16^{INK4a}$ protein is indicative for cervical cells

25   overexpressing $p16^{INK4a}$, or if there is an abundant number of endometrial cells present in

the sample, thus mimicking the overexpression of $p16^{INK4a}$. In this respect normalization

may comprise the determination of the quantity of endometrial cells within a cervical

sample on the basis of a molecular marker. Comparing the level of e.g. $p16^{INK4a}$ as a marker

for a medically relevant condition determined in a cervical sample to the quantity of

30   endometrial cells assessed by means of molecular markers, one may state, whether the total

amount of p16 may arise only from the endometrial cells present within the sample solution.

Thus false positive results in diagnosing cervical dysplasias overexpressing $p16^{INK4a}$

attributable to the presence of high levels of endometrial cells may be excluded. A quantity

24

as used in the context of the present invention may refer to a quantitative or semi-quantitative assessment. This may e.g. comprise the assessment of a total number of cells or the assessment of a fraction with respect to the total number of cells. In certain embodiments of the invention the determination of a quantity may refer to the assessment of

5   the fraction of an overall marker level that is contributed by a particular type of cells.

For the purpose of providing a normalization marker for the evaluation of cervical specimens, several normalization markers appear to be useful and may e.g. be selected from the following: Cytokeratins, E-Cadherins, Involucrin, Urokinase-like Plasminogen-activator, SCCA (Squamous cell carcinoma antigen), Catenins, (e.g. alpha-catenin, beta-

10 Catenin, gamma-Catenin (Plakoglobin)), Ep-Cam.

Several candidates for normalization markers have been examined for their properties in characterization of cervical specimens. The results are given in Table 2 and Table 3.

Table 2

Name	Histology / Cytology	Clinical/Biochemical Data	Literature
UPA-1 (Urokinase-type Plasminogen-Activator; Swissprot Accession P00749; also known as EC 3.4.21.73, U-plasminogen activator uPA)	Cervical tissue Normal epithelium showed presence of both t-PA and u-PA immunoreactivity only in the superficial cellular layer, whereas in preinvasive lesions they were present in all layers.	↑ In cervix CA	Horn LC Aust N Z J Obstet Gynaecol, 2002 Larsson G Thromb. Haemost. 1987
PAI-1 (Plasminogen-Activator Inhibitor 1; Swissprot Accession P05121; also known as PAI-1 Endothelial plasminogen activator inhibitor PAI; Isoforms: PAI-2 P05120 and PAI-3 P05154)	Cervical tissue Normal epithelium showed presence of both t-PA and u-PA immunoreactivity only in the superficial cellular layer, whereas in preinvasive lesions they were present in all layers.	↑ In cervix CA positive prognostic marker	Horn LC Aust N Z J Obstet Gynaecol, 2002 Larsson G Thromb. Haemost. 1987
Involucrin (Swissprot Accession P07476)	Only squamous epithelia, no columnar cells; immature and mature squamous metaplastic cells. In normal epidermis, it is first expressed in the upper spinous layers, and in keratinocyte cultures it is expressed by all cells that have left the basal layer.	Involucrin expression is abnormal in squamous cell carcinomas and premalignant lesions, and is reduced in severe dysplasias of the larynx and cervix. Marker for terminal differentiation.	Shirley A, Human Pathology, 2001 de Boer et al., 1999, Am J of Pathol, 155:505-515 Nair SA, Pathobiology, 1996
gamma-Catenin (Swissprot Accession Q86W21; also known as Plakoglobin; e.g. Epitope: C-Terminus; AA553-738)	Squamous epithelia	High in normal cervical epithelium at cell-cell-boundaries. Moderate reduction in high grade SILS	de Boer et al., 1999, Am J of Pathol, 155:505-515
Alpha-1 Catenin (Swissprot Accession P35221; also known as Cadherin-associated protein Alpha E-Catenin)	Squamous epithelia	High in normal cervical epithelium at cell-cell-boundaries Strong reduction in high grade SILS	de Boer et al., 1999, Am J of Pathol, 155:505-515
Alpha-2 Catenin			

(Swissprot Accession P26232; also known as Alpha-Catenin related protein Alpha N-Catenin)			
beta-Catenin (Swissprot Accession P35222 also known as PRO2286)	Squamous epithelia	High in normal cervical epithelium at cell-cell-boundaries Strong reduction in high grade SILS	de Boer et al., 1999, Am J of Pathol, 155:505-515
Desmoplakin (Swissprot Accession P15924; also known as DP 250/210 kDa paraneoplastic pemphigus antigen)	stratified epithelia, simple epithelia, including glands, urothelium, thymic reticular epithelium, hepatocytes, intercalated disks of myocardium and arachnoid cells of meninges suprabasal layers of cervix (Superficial cells largely negative)	↓ in HSIL area	de Boer et al., 1999, Am J of Pathol, 155:505-515

↓: down regulated; ↑: up regulated;

27

Table 3:

Marker	Histological testing	Cytological testing	Western Blot Analysis (clinical samples were freshly lysed with MTM buffer)
E-Cadherin (Swissprot Accession P12830; also known as Uvomorulin, Cadherin-1, CAM 120/80; e.g.epitope: C-Terminus; AA735-883)	Squamous epithelia, (Parabasal, intermediate cells) no columnar epithelia	Parabasal, intermediate cells, no columnar cells	Only weak signal for HT-29. All clinical samples are negative
p120 Swissprot Accession O60716; p120 catenin, p120(ctn), Cadherin-associated Src substrate, CAS, p120(cas); e.g.epitope: C-Terminus; AA790-911)	Squamous epithelia, (Parabasal, intermediate clls) also very strong in columnar epithelia	Very strong staining of parabasal, intermediate cells strong columnar cells	Only negative control (lymphocytes) and positive control (C4.1) positive
gamma-Catenin Swissprot Accession Q86W21; also known as Plakoglobin; e.g. epitope: C-Terminus; AA553-738)	Squamous epithelia, (Parabasal, intermediate cells) no columnar epithelia, total epithelium is stained indysplasia	Very strong staining of parabasal, intermediate cells no columnar cells	Double bands (82/95 kD) in 60 % of samples (9/15); after acetone precipitation of 150 µl of samples: 87% (13/15) positive
Ep-Cam (Tumor-associated calcium signal transducer 1, Swissprot Accession P16422; also known as Major gastrointestinal tumor-associated protein, GA733-2, Epithelial cell surface antigen, Epithelial glycoproteins, EGP, Adenocarcinoma-associated antigen KSA KS 1/4 antigen Cell surface glycoprotein Trop-1)	strong columnar epithelia, at very high concentrations rather unspecific (cytoplasmic) staining of squamous epithelia, (Parabasal, Intermediate Cells)	strong columnar cells, at very high concentrations rather unspecific (cytoplasmic) staining of squamous epithelia, (Parabasal, Intermediate Cells)	
Involucrin (Swissprot Accession P07476)	Strong staining of squamous epithelia, (Parabasal, Intermediate Cells) and columnar epithelia; unspecific staining of stromal cells;	All cells and structures positive	

28

The markers for normalization may for example be applied as markers indicative of the presence of specific cell differentiation patterns such as e.g. terminal differentiation or differentiation as specific epithelial cells. In certain embodiments, normalization markers

5 may be marker molecules characteristic for squamous epithelial cells e.g. indicative for the presence of ectocervical cells in a cervical sample. Suitable markers may comprise e.g. CK13, E-Cadherin, gamma-Catenin, or Involucrin. In another embodiment the markers may be characteristic for the presence of columnar epithelial cells indicating the presence of endocervical cells in the specimen. Suitable markers comprise: Ep-Cam, CK18, CK8.

10   In certain embodiments, normalization may comprise the detection of epithelial cells generally; in these cases any marker suitable for the detection of epithelial cells may be employed. Markers may be for example those given in Tables 2 and 3.

In yet another embodiment of the invention, the method disclosed herein may be used for the detection of disorders of the respiratory tract. In the diagnosis of small cell lung

15 cancer detection of neuron specific enolase (NSE) is one of the employed markers. Samples of tumor specimens are yielded by bronchoscopy with collection of cells by means of brushes or bronchoalveolar lavages. Since NSE is also expressed in few normal cells within the lung, the level of NSE expression detected in the dissolved sample has to be set in relation to the normalisation maker (for example actin) for detection of the amount of cells

20 present within the sample.

A third embodiment of the present invention is the detection of lesions of the gastrointestinal tract, e.g. colorectal lesions from stool samples. In this case the origin of indicative nucleic acids and/or polypeptides detectable in stool samples may be crucial for the assessment of diagnosis. According to the present invention, it is possible to determine

25 the origin (cell types/organism) of the employed marker molecules. Thus false results based e.g. on the detection of marker molecules originating from foodstuff ingested by individuals rather than from lesion of the mucosa of the gastrointestinal tract may be eliminated. Furthermore artefacts produced by the presence of traces of markers from the blood circulation, or originating from swallowed sputum etc. may be eliminated using the methods

30 disclosed herein.

Another aspect of the present invention is a testing kit for performing the method according to the present invention. The kit may be for example a diagnostic kit, an analytical kit or a research kit.

The term kit as used according to the present invention may comprise kits as well as diagnostic devices. The kits or devices may e.g. be designed for ELISA (e.g. sandwich, competitive, non-competitive, etc.), EIA (competitive, non-competitive, etc.) RIA tests, bead based test systems, lateral flow assays, flow through assays, strip test assays, dip stick

5   assays, or any other known laboratory-, bench top- or Point of care-testing format. A kit according to the present invention may in certain embodiments comprise in-vitro diagnostic devices for performing diagnostic tests. In vitro-diagnostic devices may e.g. be ELISA devices of any kind known to those of skill in the art. These devices comprise devices for sandwich ELISA formats, for competitive ELISA formats and any other ELISA formats. In

10 another embodiment the in-vitro diagnostic device may be a lateral flow assay device, or a flow through assay device e.g. employing at least one reagent binding to a marker characteristic for a medically relevant condition and one reagent binding to a normalization marker, both fixed to a solid phase. Such devices may employ various mechanisms for visualization of the test result. In certain embodiments the tests may employ secondary

15 detection reagents directed against the marker molecules coupled to detectable moieties. The detectable moieties may comprise colloidal gold, (coloured) latex particles and others.

In yet another embodiment the in-vitro diagnostic test device may be a flow through assay device based on capillaries or on porous members (such as membranes, beads or other three dimensional arrangements of porous substances). Depending on the embodiment the

20 size of pores or capillaries need to be adjusted to ensure optimal flow conditions.

A kit according to present invention may comprise

a) reagents for the detection of the marker molecules,

b) the reagents and buffers commonly used for carrying out the detection reaction, such as buffers, detection-markers, carrier substances and others,

25 c) one or more markers and/or samples representative for medically relevant conditions to be diagnosed for carrying out positive and/or control reactions, and

d) one or more normalization marker samples for carrying out a positive and/or control reaction.

The test kit may optionally include a lysis buffer for solublization of the raw sample. The

30 Generally the lysis buffer may be any suitable solvent known to those of skill in the art. The

lysis buffer for use in the kit may for example be aqueous solutions of chaotropic agents such as e.g. urea, GuaSCN, Formamid, of detergents such as anionic detergents (e.g. SDS, N-lauryl sarcosine, sodium deoxycholate, alkyl-aryl sulphonates, long chain (fatty) alcohol sulphates, olefine sulphates and sulphonates, alpha olefine sulphates and sulphonates,

5   sulphated monoglycerides, sulphated ethers, sulphosuccinates, alkane sulphonates, phosphate esters, alkyl isethionates, sucrose esters), cationic detergents (e.g. cetyl trimethylammonium chloride), non-ionic detergents (e.g. Tween 20, Nonidet P-40, Triton X-100, NP-40, Igepal CA-630, N-Octyl-Glucosid) or amphoteric detergents (e.g CHAPS, 3-Dodecyl-dimethylammonio-propane-1-sulfonate, Lauryldimethylamine oxide) and/or of

10 alkali hydroxides such as e.g. NaOH or KOH.

Examples of Lysis Buffers are given in Table 4.

Table 4:

Lysis buffer	Solubilization of $p16^{INK4a}$ in Western blot	compatibility with Elisa
Detergents:		
0.1-1% SDS	+	+/-
0.2-3% SDS	+	< 0.5 %
0.2-3% DOC	++	+/-
0.1-1% n-Octylglycoside	+	yes
0.1-3% Triton x-100%	+	yes
0.1-1% Chaps	+	nd

Detergent-Mix:

RIPA (1%NP40, 0.5%DOC, 0.1%SDS, PBS) 40-100%	++	yes
SOX (0.5% DOC, 0.5% n-Octylglycoside) 40-100%	+	yes
mtm lysis buffer (3% Tritonx-100, 0.4 % SDS, PBS)	++	yes

Commerical lysis buffers:

Dynal (Dynal, Oslo, Norway)	++	yes
M-PER/B-PER (Pierce, Rockford, IL)	++	yes

Miscellaneous:

0.5-8 M urea in PBS	+++	Compatible< 2 M
Lämmli sample buffer	+++	no
10-80% DMSO	+++	no
10-80 % Formamide	nd	no
50-70% formic acid	++	no
PBS	+/-	yes
Citrate buffer pH 6.0	+/-	yes
500 mM NaCl in Phosphate buffer	+/-	yes

nd: not determined; +/-: poor; +: good; ++: very good; +++: excellent;

The lysis buffer may furthermore comprise one or more agents that prevent the degradation of components within the raw samples. Such components may for example comprise

enzyme inhibitors such as proteinase inhibitors, RNAse inhibitors, DNAse inhibitors etc. The inhibitors may e.g. comprise proteinase inhibitors selected from the compositions given in Table 5. In certain embodiments the lysis buffer by the way of providing an inhibitor of degradation enables for detection of p16 in the sample. In certain embodiments the cyclin dependent kinase inhibitor p16 is degraded in the solubilized samples and may thus not be detected. This is especially true, if the samples are directly transferred to a lysing medium and stored therein for a certain period of time.

Table 5:

Inhibitor	Class of inhibited proteinase	concentration	Solubility in water	stability in water
Aprotinin	Serine	0.6-2 µg/ml	Very good	good
Benzamidine	Serine	0.5-4 mM	good	good
Bestatin	Aminopeptidases	1-10 µM	good	good
Calpeptin	Cysteine	0.3-1 µM	good	good
Cystatin	Cysteine	1 µM	good	good
E-64	Cysteine	1-10 µM	good	good
EDTA	Metallo	0.5-5 mM	good	good
Elastatinal	Serine	0.5-2 µg/ml	poor	good
EST	Cysteine	20-50 µg/ml	bad	poor
Fetal calf serum	all classes	10%	good	good
Leupeptin	Serine/Cysteine	10-100 µM	good	good
a2-Macroglobulin	all classes	1 µM	good	good
NCO-700	Cysteine	0.5-100 mM	poor	poor
Pefabloc= AEBSF	Serine	0.2-10 µM	good	very poor

Pepstatin A	Aspartic	1 µM	bad	poor
PMSF	Serine	0.2-10 µM	bad	very poor
o-Phenanthroline	Metallo	1-10 mM	bad	poor

For stabilization purpose the lysis buffer may also comprise bulk protein (e.g. albumin such as bovine serum albumin or calf serum albumin or other bulk proteins) to compete in degradation with the sample proteins. The bulk proteins may e.g. be present in

5   combination with proteinase inhibitors or may be added instead of proteinase inhibitors. In one embodiment the solvent may be selected to be compatible with the performance of the test (EIA, ELISA or strip test performance), so that solubilized samples may directly be applied to the test. Test as used in the context may comprise any procedure for detecting the presence or absence and/or the level of marker molecules.

10   The reagent for the detection of the marker molecules may include any agent capable of binding to the marker molecule. Such reagents may include proteins, (poly)peptides, nucleic acids, peptide nucleic acids (PNAs), glycoproteins, proteoglycans, polysaccharids or lipids.

The markers characteristic for medically relevant conditions and/or normalization

15   marker samples for carrying out positive and/or negative controls may comprise for example nucleic acids in applicable form such as solution or salt, peptides in applicable form, tissue section samples, microorganisms or positive or negative cell-lines.

In one embodiment of the invention, the detection of the marker molecules is carried out on the level of polypeptides. In this embodiment the binding agent may be for example

20   an antibody specific for the marker molecules or a fragments thereof. Furthermore binding agents may comprise antigen-binding fragments such as Fab fragments, single chain antibodies, bifunctional hybrid antibodies, peptidomimetics containing minimal antigen-binding epitopes etc. Moreover the binding agent might be a lectin binding to a specific carbohydrate structure on the marker molecule.

25   In another embodiment of the test kit the detection of the marker molecules is carried out on the nucleic acid level. In this embodiment of the invention the reagent for the

34

detection may be for example a nucleic acid probe or a primer reverse-complementary to said marker nucleic acid.

The following examples are given for the purpose of illustration only and are not intended to limit the scope of the invention disclosed herein.

5

EXAMPLES

Example 1: Specific immunohistochemical detection of endocervical and ectocervical epithelial cells in cervical sections

In order to evaluate markers indicating the adequacy of cervical swabs, cervical
10 sections (fixed in 4 % formaldehyde solution and paraffin-embedded) were stained with antibodies directed against Cytokeratin 18 (marker for endocervical columnar epithelia) and Cytokeratin 10/13 (marker for ectocervical squamous epithelia). Figure 1 shows specific staining of endocervical epithelia with anti-Cytokeratin 18 antibody and specific staining of ectocervical epithelia with anti-Cytokeratin 10/13 antibody. The experiment was performed
15 as follows:

Formalin-fixed, paraffin-embedded sections were deparaffinized in xylene bath for 5 min (step was repeated once), excess liquid was tapped off and slides were placed in 95-96% ethanol for 3 ($\pm$1) min, in 70% ethanol for 3 ($\pm$1) min (step was repeated once) and finally in distilled water for a minimum of 30 sec. For epitope retrieval, slides were placed
20 in a Coplin jar and boiled for 40 min at 95-99°C in 10 mM Citrate buffer pH 6.0. Slides were allowed to cool down for 20 min ($\pm$1 min) at RT in this buffer. Slides were covered with Peroxidase-Blocking Reagent (3% H_2O_2; NaN$_3$ 15 mM) and incubated for 5 ($\pm$1) min at RT. After 5 min washing in washing buffer, slides were incubated with primary antibodies (CK 10/13: DE-K13, 1:50, DAKO; CK 18: K18.7, 1 μg/ml, dianova) for 30 min.
25 Thereafter, slides were rinsed with wash buffer and washed in wash buffer for 5 min at RT. Following 30 min incubation with EnVision (ready to use anti-mouse horseradish peroxidase-complex; DAKO), slides were washed 3x5 min and incubated in DAB substrate for 10 min, counterstained with hematoxylin and mounted with Faramount mounting medium.
30   Using an antibody directed against cytokeratin 18 (CK18) in an immunohistochemical staining procedure, a positive reaction was detected in columnar

epithelium of the endocervix (Figure 1A), whereas the squamous epithelium of the ectocervix showed no specific staining (Figure 1B). Immunohistochemical staining with an antibody directed against cytokeratin 10/13 (CK 10/13) showed no staining in the columnar epithelium of the endocervix (Figure 1C), whereas there is a strong staining of the

5   squamous epithelium of the ectocervix (Figure 1D). So CK18 might be used as a specific marker for the detection of columnar epithelial cells of the endocervix and CK10/13 as a specific marker for squamous epithelial cells of the ectocervix.

10   **Example 2: Western Blot analysis of solubilized samples from cervical swabs**

In order to evaluate, whether western blot analysis of solubilized samples allows assessing diagnosis of cervical lesions, clinical samples with known diagnosis were subjected to an immuno-chemical analysis on the basis of marker molecules after lysis of the sample material.

15   The clinical material (cervical swabs) samples were analyzed by Standard Western Analysis as follows.

In brief, the clinical material was in a first step solubilzed by boiling (5min, 95°C) in Lämmli Protein Sample buffer (100 mM Tris pH.6.8, 2% SDS, 200mM DTT, 0.05% BpB) prior to sonification. In a second step, protein samples were resolved on a SDS-PAGE (12%

20   Acrylamide) and subsequently transferred on a nitrocellulose membrane by tank blotting (Towbin et al., 1979, Proc Natl Acad Sci: 76:4350-4354). In a further step, the membranes were: blocked to prevent unspecific antibody binding (10% non fat dry milk in PBS) and subsequently incubated with the specific monoclonal mouse antibody (CK 8: 35ßH11, 1:100, DAKO; p16^{INK4a}: D7D7, 1:140, MTM Laboratories). The binding of the specific

25   antibody was visualized by Horseradish Peroxidase conjugated secondary reagents (binding to the marker specific antibody) catalyzing photon emitting substrates.

Cytokeratin 8 (CK 8) was used as an endocervical cell specific marker, indicating the adequacy of the sample collection in the present experiments. The cyclin dependent kinase inhibitor p16^{INK4a} was used as specific disease related marker.

30   The results of the present experiment are given in Figure 2. The numbers 1 to 4 refer to samples (cervical swabs) obtained from individual patients. Immunoblot detection was performed using specific antibodies directed against cytokeratin 8 (CK8) and specific

antibodies directed against p16^{INK4a} (p16). The samples of patient 1, 2, and 3 show no signal

for p16^{INK4a}. This indicates that no dysplastic cervical cells were present in these samples.

The sample of patient 4 shows a strong signal for p16^{INK4a}. This indicates that dysplastic

cervical cells were present in the sample. The upper bands show the specific signals for

5   cytokeratin 8. In sample 1,3, and 4 cytokeratin 8 can be detected, whereas in for sample 2

no signal can be seen. This indicates that endocervical columnar cells were present in

samples 1, 3, and 4, and absent in sample 2. As the presence of endocervical columnar

epithelial cells is one of the parameters for the adequacy of cervical swabs, sample 2 is

considered inadaequat and no diagnostic conclusions can be drawn from the negative result

10   of the p16^{INK4a} detection. Samples 1, 3, 4 are considered adequate. So based on the negative

signal of sample 1 and 3 for p16^{INK4a} it could be concluded, that these patients had no

cervical dysplasia. Sample 4 showed a positive signal for p16^{INK4a}, indicating the presence

of a dysplastic cervical lesion in this patient.

The parallel cytological analysis of the swabs indicated a normal cellular

15   composition for woman 1 and 3. In women 2, no diagnosis due to sparse cellular material

could be obtained. In woman 4, a high-grade dysplasia was diagnosed. Note that the upper

band (CK 8) refers to the endocervical cell specific normalization marker Cytokeratin 8,

indicating the adequacy of the sample collection. The lower band indicates the specific

disease related marker p16^{INK4a}. The blot shows for patient 4 a positive signal for p16^{INK4a}

20   consistent with a high-grade cervical dysplasia. Samples of patient 1 and 3 show only the

CK 8 specific band, indicating proper sample collection, but no disease related marker

(p16^{INK4a}) consistent with a normal, healthy cervical epithelium. The sample of patient 2

shows no CK 8 signal, consistent with the low cell number in this sample, so no diagnostic

conclusion can be drawn from the negative signal for p16^{INK4a} .

25

Example 3: Western blot and ELISA analysis to demonstrate sample adequacy

To evaluate, whether results of solution based analysis differing from diagnosis of

samples may be due to inadequacy of sample, Western blot analysis of cervical swabs of

30   four different patients with ascertained diagnosis (high-grade cervical intraepithelial

neoplasia according to the cytological diagnosis of Pap IVa and Pap IVb) was performed.

Antibody against p16^{INK4a} was used to indicate presence of dysplastic cells, whereas

antibodies against CK18 and CK10/13 were used to demonstrate adequacy of the sample.

Western blot analysis was performed as follows: Patient samples were collected with

a cervical brush and directly lysed in Laemmli Sample Buffer (2% SDS, 60mM Tris pH.6.8,

0.01%, 100 mM DTT) for 5 min at 95°C (1×10^7 cells/ml) with subsequent sonification

(5x5sec pulses, maximum intensity). Lysates were centrifuged for 12 min at 16,600xg) in a

5   microcentrifuge and supernatant was transferred into a new tube. Precast 4-20% linear

gradient Acrylamide gels (Criterion System, Bio-Rad) were loaded with 10μl (10^5 cells) of

whole cell extracts and proteins were separated at 25mA constant current for 45 min.

Proteins were transferred from the gel to Hybond ECL Nitrocellulose membrane

(Amersham) by standard tank blotting using the Bio Rad Criterion Blotter (15 min at

10 constant 100 Volt and subsequently 45min at constant 50 Volt). Nitrocellulose-membrane

was stained for 5 min in Ponceau S solution to assure protein transfer. Ponceau S solution

was removed by 2x10 min washes in PBS. For immunodetection, blots were blocked over

night in blocking buffer (10% milk powder in PBS with 0.1% Tween-20). Primary

antibodies were incubated at dilutions according to the manufacturer in blocking buffer for

15 1 h at RT with agitation (CK18: MAB 3236), 1:1000, CHEMICON; CK 10/13: DE-K13,

1:500, DAKO, p16^{INK4a}: D7D7, 1:140, MTM Laboratories). After 6 washes for 10 min with

PBS/0.1% Tween-20, blots were incubated with rabbit anti mouse-HRP, (DAKO, diluted

1:5,000 in blocking buffer) for 1 h at RT. After 6 washes for 10 min with PBS/0.1% Tween-

20, membranes were incubated for 5 min in substrate solution (Super Signal West Femto

20 Maximum Substrate, Pierce), wrapped in a plastic envelope and exposed to an x-ray film

for 1-5 min. Finally, x-ray films were developed, fixed, dried and documented with an

imaging system (Bio-Rad). The same samples were used to perform ELISA analysis for

p16^{INK4a}, CK 10/13, CK18. The detected signals and results were the similar to the Western

blot analysis and the same conclusions were drawn.

25   The ELISA analysis was performed as follows: Flat bottom 96 well plates

(MaxiSorb; Nunc) were coated with capture antibody (p16^{INK4a}: MTM-E6H4, 2μg/ml in

PBS, MTM Laboratories; CK10: MS481P1ABX, 2μg/ml, dianova; CK18: K18.7, 2□g/ml,

dianova; 50μl/well) over night at 4°C. Plates were washed 6x with PBS/0.1% Tween-20 and

blocked with Superblock buffer (Pierce). Solubilized protein extract from cervical swabs

30 were dissolved in incubation buffer (PBS, 3% Superblock, 0.1% Tween20), and added in

triplicates to each well. After 1 h incubation at RT, plates were washed 6x with PBS/0.1%

Tween-20 and incubated with biotinylated detection antibody (p16^{INK4a}: MTM-D7D7 (0.2

μg/ml, MTM Laboratories, CK10: MS481-BO, 200 μg/ml, dianova; CK18: MS142-BO,

38

200 μg/ml, dianova; in incubation buffer) for 1 h at RT. Following 6x washes with
PBS/0.1% Tween-20 TMB, 50 μl of Streptavidin-coated Alkaline Phosphatase (1:1000
dilution; Dianova) was added for 30 min. Thereafter, plates were washed 6x with PBS/0.1%
Tween-20 and 100 μl of p-nitrophenyl phosphate substrate (PnPP; dissolved in diethanol
5 amine buffer) were added to each well. OD 405 nm (620 nm reference wavelength) was
measured with an ELISA reader (Tecan) after 30 min, 1h and 2 hrs. The present example
shows, that the sandwich ELISA format exhibits sensitivity, which is suitable for the use in
the methods according to the present invention. For use in the method disclosed herein the
sandwich ELISA format as described in this example may be applied to multiple marker
10 molecules, such as markers for normalization/adequacy and markers characteristic for
medically relevant conditions.

Samples of four patients with high-grade cervical dysplasias (see Diagnosis) were
analysed using western blot analysis (upper panel of figure). For the left blot immunoblot
detection was performed using antibodies specific for β-actin and p16^{INK4a}, for the middle
15 blot antibodies specific for cytokeratin 10/13 and for the right blot antibodies specific for
cytokeratin 18 were used. ß-actin, CK18, and CK10/13 were used as markers
demonstrating the adequacy of the sample. ß-actin indicates the presence of any cells,
CK10/13 the presence of ectocervical squamous cells, CK 18 the presence of endocervical
columnar cells.

20   As shown in Figure 3, for the samples of patient 1 and 2, the immunoblot detections
show positive signals for all the applied adequacy markers (CK10/13, CK 18, ß-actin) and
for the marker (p16^{INK4a}) indicative of dysplastic cells. Samples 3 and 4 were negative for
p16^{INK4a} bands in Western blot. However, in these cases the ß-actin and the two cytokeratin
markers showed an extremely weak (patient 3, ß-actin) or negative (patient 4, all markers;
25 patient 3, CK markers) signal in the Western blot analysis. So no diagnostic conclusion can
be drawn from the negative signal for p16^{INK4a}.

The lower panel of this figure shows the results of ELISA analysis. Positive signals
for the adequacy markers (CK10/13, CK 18) were detected for the sample of patient 1 and
2, whereas for the samples of patients 3 and 4 no signals for CK10/13 and CK 18 was seen.
30 So the ELISA analysis results resemble the Western blot analysis results and the same
conclusions can be drawn.

Example 4: Western blot analysis of different samples of pulmonary origin

39

In order to evaluate, whether Western blot analysis of solubilized samples allows to assess diagnosis of pulmonary lesions, clinical samples with known diagnosis were solubilized and subjected to an immuno-chemical analysis on the basis of marker and normalization molecules.

5   The clinical samples (cells collected by brushing or bronchoalveolar lavage) were analyzed by Standard Western Analysis as follows. Cells from bronchoalveolar lavage were pelleted by centrifugation (5 min, 1000 rpm) and the pellet was dissolved in Lämmli Protein Sample buffer (100 mM Tris pH.6.8, 2% SDS, 200mM DTT, 0.05% BpB). Cells obtained by brushing were dissolved directly in Lämmli Protein Sample buffer (100 mM Tris pH.6.8,

10   2% SDS, 200mM DTT, 0.05% BpB). The material was boiled (5min, 95°C) prior to sonification. In a second step aliquots of the protein samples were resolved in duplicates on a SDS-PAGE (12% Acrylamide) and subsequently transferred on a nitrocellulose membrane by tank blotting (Towbin et al., 1979, Proc Natl Acad Sci;76:4350-4354). In a further step the membranes were blocked to prevent unspecific antibody binding (10% non

15   fat dry milk in PBS) and subsequently one membrane was incubated with specific monoclonal mouse antibodies against NSE (DAKO Germany, clone BSS/NC/VI-H14, mouse monoclonal, dilution 1:1000;) and one membrane was incubated with the normalization marker actin (ICN, USA, clone C4, mouse monoclonal, dilution 1:400). The binding of the specific antibody was visualized by Horseradish Peroxidase conjugated

20   secondary reagents (binding to the marker specific antibody) catalyzing photon emitting substrates.

In the bronchoalveolar lavages of patients with known small cell lung cancers high levels of NSE in comparison with the expression levels of actin was detected, whereas in patients without tumor hardly any NSE could be detected, the actin level however was

25   comparable to the level of the cancer patients. (Data not shown)

The results indicate, that a normalization of the solution based testing procedure according to the method presented herein enables for assessing diagnosis of diseases without relying on morphological information

30   **Example 5:   Detection of Cervical Intraepithelial Neoplasia in an ELISA test format**

40

34 cervical swabs provided in lysis buffer have been subjected to ELISA based detection of overexpression of cyclin dependent kinase inhibitor p16^{INK4a} in solutions prepared from the cells contained in the swabs. The ELISA testing was performed as follows:

5   *(A)   Cell Lysis*

Cervical swab brushes are given into 15 ml vessels, containing 2 ml of mtm lysis buffer. Cervical cells present in the brush are lysed for at least 20h. The lysates of the cervical swab samples are then transferred in 2 ml tubes and are centrifuged at 4°C (15 min at 28.000 x g (16.600rpm Highspeed Centrifuge JEC Multi RF)); Supernatant is transferred

10 to a fresh tube. As the case may be the supernatant may be stored at -20 °C.

(B)   Performing the ELISA

Coating of ELISA-plates

Stock-solutions of p16^{INK4a}-specific antibody clone mtm E6H4, Ep-Cam specific antibody Ber-Ep4 and gamma-Catenin specific antibody clone 15 are diluted in PBS to give

15 ready-to-use coating solution.

50µl of each ready-to-use capture antibody coating solution is added to ELISA plates.

For coating, the plates are incubated overnight at 4°C.

Coating solutions are removed from the ELISA plates and the plates are rinsed using

20 an automated ELISA washer as follows:

·   7 x 250µl washing buffer (0.1% Tween20 (v/v) in PBS)

after removing remnants of the washing buffer, 300µl blocking buffer (2% BSA in PBS) is added to each well. Plates are incubated for 1h on a rocking device at ambient temperature.

25   ·   *Incubation with samples*

After removing the blocking buffer 100µl of the lysed cell sample is added to each well. Lysates of HeLa-cells are used as positive control for antibodies specifically detecting p16^{INK4a} and gamma-Catenin; Lysates of HT29-cells are used as positive control for antibodies specifically detecting Ep-Cam;

30   For purpose of calibration of the test, different concentrations of recombinant p16 protein, recombinant gamma-Catenin and and Ep-Cam (0 pg/ml, 50 pg/ml, 100 pg/ml, 200 pg/ml, 400 pg/ml, 800 pg/ml) are included in the test.

Samples are incubated for 1 h at room temperature.

Thereafter washing is performed on an automated ELISA washer as follows

- 7 x 250μl washing buffer. The remaining buffer is removed.

Incubation with detection antibody

Working solutions of biotinylated secondary antibodies (clone mtm D7D7 specific

5 for p16^{INK4a}, clone A5B4 for Ep-Cam and clone MAB 2083 specific for gamma-Catenin)

are prepared by dilution of stock solutions.

100μl of working solutions of biotinylated secondary antibodies are added to wells

incubated with corresponding antigen and capture antibody. After incubation for 1h at RT,

antibody solutions are removed and ELISA plates are washed by an automated ELISA

10 washer

- 7 x with 250μl washing buffer.

Detection

Streptavidin-HRP-polymers (1mg/ml) are pre-diluted 1:10 (4μl +36μl incubation

buffer); Final incubation solution is prepared by dilution 1:300 in incubation buffer (0,1%

15 BSA in PBS) to a final concentration of 0,33 μg/ml.

100μl of this solution are added to each well and incubated for 1 h at RT.

Thereafter, the buffer is removed and the plates are washed manually with 200 μl

washing buffer per well 5 times.

Substrate incubation

20   TMB-substrate is equilibrated to 25°C for 1h in the dark.

100μl of substrate solution is added to each well.

The ELISA plates are incubated at 25°C for exactly 15 min in the dark. Then the

reaction is stopped by addition of 80 μl 2,5M H2SO4.

Within 5 min. after stopping the reaction OD 450 nm is determined. After evaluation

25 of the results, each sample returns a value for the OD.

Evaluation of results

For sample adequacy, OD values of all samples for gamma-Catenin have to exceed a

defined threshold value to prove proper sampling of a minimum of cells. Furthermore to

ensure proper sampling a threshold for the OD value of Ep-Cam indicating the presence of

30 endocervical cells has to be exceeded.

For detection of dysplastic cells, OD values for p16^{INK4a} have to exceed a defined

threshold value to prove the presence of a minimum of p16-positive dysplastic cells.

Results of this experiment are given in Table 6.

Table 6

No. of samples	P16^{INK4a}	Gamma-Catenin	Conclusion
3	+	+	Sample is adequate; p16^{INK4a} indicates the presence of dysplastic cells
30	-	+	Sample is adequate; absence of detectable p16^{INK4a} indicates absence of dysplastic cells
1	-	-	Sample is inadequate; re-sampling necessary

Comparison of OD values for p16^{INK4a} and gamma-Catenin of 34 samples with corresponding threshold values revealed that 33 samples were adequate and could be further

5   evaluated. From theses 33 samples, 30 samples were negative for p16^{INK4a} and 3 were positive.

The ELISA results were compared to the diagnostic results of a Papanicolaou test (PAP test, cervical cytology) from the same patients. The cervical cytology were evaluated according to the Munich Classification II (1990). Pap II encompasses benign cells, cervicitis

10   and metaplasia, Pap IV encompasses severe dysplasia and carcinoma in situ. It turned out that samples returning an OD for p16^{INK4a} of greater than 0.9 in the ELISA correspond to samples, that are classified as dysplastic by the conventional cytological PAP test.

Applying OD 0.9 as threshold for the evaluation of the samples the ELISA results may be reported as follows.

15   **Table 7**

Diagnosis/ELISA results	ELISA positive for p16^{INK4a}	ELISA negative for p16^{INK4a}
Pap II	0	30
Pap IV	3	0
Not enough cells	0	1

The ELISA test is positive in all 3 samples (100%) from women having severe dysplasia and is negative in all 30 samples (100%) of women having no dysplasia. One sample only contained very few cells and therefore was excluded from evaluation, since

20   sampling was inadequate.

The normalization of p16^{INK4a} protein levels in solubilized patient samples with respect to a normalization marker characteristic for the presence of epithelial cells allows to assess diagnosis of dysplasias from the samples. The normalization in the present case

allows especially to avoid false negative results due to inadequate sampling (for example total amount of patient material not sufficient to perform analysis, or the patient material is not taken at the correct anatomical location). The normalization is carried out in the testing format by applying a threshold value for the OD for the gamma-Catenin normalization

5   marker determined in the ELISA above which the sample is to be classified as adequate. Below a certain threshold (corresponding to 200.000 squamous ectocervical cells) the sample does not contain an adequate amount of patient material. The use of a second normalization marker indicating the presence of endocervical cells provides further information about the adequacy of the sample. The normalization is carried out in the

10 testing format by applying a threshold value for the OD for the Ep-Cam normalization marker determined in the ELISA above which the sample is to be classified as adequate. Below a certain threshold (corresponding to 2000 columnar endocervical cells) the sample does not contain an adequate amount of endocervical cells. (It must be understood that the threshold value applied in this example are adjusted to the particular reaction conditions.

15 The value for the cells as well for OD may vary depending to the reaction conditions. Thus the values herein are intended to exemplify the conditions and not to limit the scope of the invention. Those of skill in the art know how an appropriate threshold value for a particular test format may be established.) The presence of endocervical cells provides the information that the swab or brush has had contact with the columnar epithelium of the endocervix and

20 thus hints to a contact of the swab or brush with the transformation zone, where cervical dysplasia usually originates. In particular the detection of a certain amount of ectocervical cells (gamma-catenin) together with a certain amount of endocervical cells (Ep-Cam) provides with a high probability the information that the patient material was taken at the correct anatomical location (cervical transformation zone).

25   Using the threshold values evaluated in these experiments, cytological specimens of 300 patients were tested in the presented ELISA testing format. In this experiments the specimens identified as being dysplastic by cytological examination may also be identified as being dysplastic in the ELISA testing format.

30

Example 6:   Detection of Cervical Intraepithelial Neoplasia in an ELISA test format.

44

The 34 cervical swabs as already used in Example 5 provided in lysis buffer have been subjected to ELISA based detection of overexpression of HPV E7 Protein and one adequacy marker in solutions prepared from the cells contained in the swabs. The ELISA testing was performed as follows:

5   *(A)   Cell Lysis*

Cervical swab brushes are given into 15 ml vessels, containing 2 ml of mtm lysis buffer. Cervical cells present in the brush are lysed for at least 20h. The lysates of the cervical swab samples are then transferred in 2 ml tubes and are centrifuged at 4°C (15 min at 28.000 x g (16.600rpm Highspeed Centrifuge JEC Multi RF));Supernatant is transferred

10   to a fresh tube. As the case may be the supernatant may be stored at -20 °C.

(B)   Performing the ELISA

Coating of ELISA-plates

Stock-solutions of E7-specific antibody clone NM2 and gamma-Catenin specific antibody clone 15 are diluted in PBS to give ready-to-use coating solution.

15   50µl of each ready-to-use capture antibody coating solution is added to ELISA plates.

For coating, the plates are incubated overnight at 4°C.

Coating solutions are removed from the ELISA plates and the plates are rinsed using an automated ELISA washer as follows:

20   ·   7 x 250µl washing buffer (0.1% Tween20 (v/v) in PBS)

after removing remnants of the washing buffer, 300µl blocking buffer (2% BSA in PBS) is added to each well. Plates are incubated for 1h on a rocking device at ambient temperature.

Incubation with samples

25   After removing the blocking buffer 100µl of the lysed cell sample is added to each well. Lysates of HeLa-cells are used as positive control for antibodies specifically detecting gamma-Catenin; For purpose of calibration of the test, different concentrations of recombinant HPV 16 E7-protein, recombinant gamma-Catenin (0 pg/ml, 50 pg/ml, 100 pg/ml, 200 pg/ml, 400 pg/ml, 800 pg/ml) are included in the test.

30   Samples are incubated for 1 h at room temperature.

Thereafter washing is performed on an automated ELISA washer as follows

·   7 x 250µl washing buffer. The remaining buffer is removed.

Incubation with detection antibody

Working solutions of biotinylated secondary antibodies (clone NM13 specific for HPV16 E7 protein and clone MAB 2083 specific for gamma-Catenin) are prepared by dilution of stock solutions.

100µl of working solutions of biotinylated secondary antibodies are added to wells

5   incubated with corresponding antigen and capture antibody. After incubation for 1h at RT, antibody solutions are removed and ELISA plates are washed by an automated ELISA washer

·   7 x with 250µl washing buffer.

Detection

10   Streptavidin-HRP-polymers (1mg/ml) are pre-diluted 1:10. (4µl +36µl incubation buffer); Final incubation solution is prepared by dilution 1:300 in incubation buffer (0,1% BSA in PBS) to a final concentration of 0,33 µg/ml.

100µl of this solution are added to each well and incubated for 1 h at RT.

Thereafter, the buffer is removed and the plates are washed manually with 200 µl

15   washing buffer per well 5 times.

Substrate incubation

TMB-substrate is equilibrated to 25°C for 1h in the dark.

100µl of substrate solution is added to each well.

The ELISA plates are incubated at 25°C for exactly 15 min in the dark. Then the

20   reaction is stopped by addition of 80 µl 2,5M H2SO4.

Within 5 min. after stopping the reaction OD 450 nm is determined. After evaluation of the results, each sample returns a value for the OD.

Evaluation of results

For sample adequacy, OD values of all samples for gamma-Catenin have to exceed a

25   defined threshold value to prove presence of a minimum of epithelial cells. (cf. Example 5)

For detection of dysplastic cells, OD values for HPV 16 E7 have to exceed a defined threshold value to prove the presence of a minimum of transformed cells. The threshold depends on the ELISA conditions applied and was set as OD 0,7 in our test format.

Comparison of OD values for HPV 16 E7, gamma-Catenin of 34 samples with

30   threshold values revealed that the 33 samples proven to contain epithelial cells by means of detection of gamma-Catenin.

46

Although the invention has been described with reference to the presently preferred embodiments, it should be understood that various modifications could be made without departing from the scope of the invention.

47

What is Claimed is:

1.   A method for diagnosing a medically relevant condition of a patient, comprising the steps of:

(a) obtaining a raw sample containing cells or cell debris from a patient;

(b) preparing a sample solution from the raw sample;

(c) detecting the levels of one or more relevant markers characteristic for said medically relevant condition in said sample solution;

(d) detecting the levels of one or more normalization markers characteristic for at least one of the following normalization parameters:

- the presence or absence of a particular cell type among the cells represented within the sample solution,

- the presence or absence of a particular differentiation pattern in the cells represented within the sample solution,

- the presence or absence of particular proliferation properties of the cells represented within the sample solution,

(e) normalizing the detected levels of said one or more relevant markers with respect to said at least one of the normalization parameters; and

(f) diagnosing the medically relevant condition based on the normalized levels of the relevant markers to the normalization parameters.

2.   A method according to Claim 1, wherein the medically relevant condition is a condition characterized by a property selected from the group consisting of the presence or absence of particular cell types in a sample, the presence or absence of a particular differentiation pattern related to cells within the sample, and the presence or absence of proliferative characteristics of cells within the sample.

3.   The method according to Claim 2, wherein the medically relevant condition is a disease.

4.   The method according to Claim 3, wherein the disease is a cell proliferative disorder, cancer or a precursory lesion.

5.   The method according to Claim 4, wherein the cancer is cancer of the head and the neck, cancer of the respiratory tract, cancer of the gastrointestinal tract, cancer of the skin and its appendages, cancer of the central and peripheral nervous system, cancer of the urinary system, cancer of the reproductive system, anogenital cancer, cancer of the

48

endocrine system, cancer of the soft tissues and bone, or cancer of the lymphopoietic and hematopoietic system.

6.   The method according to Claim 1, wherein the raw sample is blood, a secretion, a swab, an aspirate, a lavage, sputum, saliva, stool, bile, a cell, a tissue, a biopsy or a body fluid.

7.   The method according to Claim 6, wherein the sample contains cells of an eukaryotic or prokaryotic organism.

8.   The method according to Claim 1, wherein the one or more relevant markers are selected from the group consisting of cell cycle regulatory proteins, metalloproteinases, transmembrane proteins, calcium binding proteins, growth factors, marker molecules characteristic for viral infections, cell proliferation markers, and markers associated with DNA replication, tumor marker proteins, and the nucleic acids coding for the respective proteins.

9.   The method of Claim 8, wherein the tumor marker proteins are selected from the group consisting of cyclin dependent kinase inhibitors, p53, pRb, p14ARF, cyclin E, cyclin A, cyclin B, MN, her2/neu, mdm-2, bcl-2, EGF-Receptor, MCM2, MCM3, MCM4, MCM5, MCM6, MCM7, CDC2, CDC6, CDC7 protein kinase, CDC14 protein phosphatase, Dbf4, PCNA, Ki67, KiS1, Id1, osteopontine, GRP, renal dipeptidase, and TGFßII receptor.

10.   The method according to Claim 9, wherein the cyclin-dependent kinase inhibitor is selected from the group consisting of p16^{INK4a}, p13.5, p14, p15, p19, p21, p27.

11.   The method according to Claim 8, wherein the marker molecules characteristic for viral infections are a viral protein or a viral nucleic acid.

12.   The method according to Claim 11, wherein the viral protein or the viral nucleic acid is a HPV protein or a nucleic acid derived from a HPV gene selected from the group consisting of HPV L1, HPV L2, HPV E1, HPV E2, HPV E4, HPV E5, HPV E6 and HPV E7.

13.   The method according to Claim 1, wherein the one or more normalization markers are selected from the group consisting of cell surface proteins, housekeeping genes, receptor proteins, glycoproteins and/or proteoglycans, carbohydrate structures specific for glycoproteins and/or proteoglycans, cell cycle regulatory proteins, metalloproteinases, transmembrane proteins, calcium binding proteins, growth factors, cell differentiation markers, and proteins associated with DNA replication.

14.   The method according to Claim 13, wherein the one or more normalization markers are an epithelial antigen, a cytokeratin or a CD antigen.

15.   The method according to Claim 13, wherein the one or more normalization markers are selected from the group consisting of a glycoprotein, a proteoglycan, and a carbohydrate structure present on these molecules.

16.   The method according to Claim 13, wherein the one or more normalization markers are an enzyme involved in the biosynthesis of glycoproteins and/or proteoglycans.

17.   The method of Claim 1, wherein the detection of the relevant markers or the normalization markers is performed using at least one probe specifically recognizing and binding to said marker molecules.

18.   A method according to Claim 17, wherein at least one probe is detectably labelled.

19.   The method according to Claim 18, wherein the probe is labelled by a radioisotope, a bioluminescent compound, a chemiluminescent compound, an electroluminescent compound, a fluorescent compound, a metal chelate, an enzyme, or a biologically relevant binding structure.

20.   The method according to Claim 19, wherein the biologically relevant binding structure is biotin, streptavidin or digoxygenin.

21.   The method according to Claim 17, wherein said at least one probe is a binding agent.

22.   The method according to Claim 21, wherein said binding agent specifically binds to a marker polypeptide.

23.   The method according to Claim 21, wherein the binding agent is an antibody, an antibody fragment, a miniantibody, or a peptidomimetic comprising an antigen binding epitope.

24.   The method according to Claim 17, wherein said at least one probe is a lectin comprising a carbohydrate binding site, or a carbohydrate specifically recognized by a lectin.

25.   The method according to Claim 17, wherein said at least one probe is a nucleic acid molecule complementary or reverse-complementary to a marker nucleic acid and wherein said probe is specifically hybridizing to said marker nucleic acid.

26.   The method according to Claim 25, wherein the detection comprises a quantitative or semi-quantitative amplification reaction.

27.   A test kit for diagnosing a medically relevant condition comprising:

      (a)   at least one reagent for the detection of at least one marker molecule characteristic for a medically relevant condition; and

(b)   at least one reagent for the detection of at least one normalization marker characteristic for at least one of the following parameters:

the presence or absence of a particular cell type or differentiation,

pattern in the cells represented within the sample solution, and

the presence or absence of particular proliferation properties of the cells represented within the sample solution; and

(c)   a buffer for solubilizing samples.

28.   The test kit according to Claim 27, wherein at least one reagent is fixed to a solid phase.

29.   A test kit according to Claim 27, furthermore comprising at least one of the following components:

(a)   at least one marker molecule for carrying out positive control reactions selected from the group consisting of:

(i)   relevant marker molecules characteristic for medically relevant conditions,

(ii) normalization marker molecules characteristic for at least one of the following parameters:

- the presence or absence of a particular differentiation pattern in the cells represented within the sample solution

- the presence or absence of particular proliferation properties of the cells represented within the sample solution; and

(b)   reagents and buffers commonly used for carrying out the detection reaction.

30.   A test kit according to Claim 27, wherein the reagents for detection of marker molecules comprise binding agents specific for said marker molecules and/or nucleic acid probes hybridizing to nucleic acids coding for said marker molecules.

31.   The test kit according to Claim 30, wherein the binding agents are an antibody, a miniantibody, or a peptidomimetic comprising an antigen binding epitope.

32.   The test kit according to Claim 27, wherein the test kit is a diagnostic test kit, a research kit, or an analytical kit.

33.   A method for diagnosing cervical dysplasia, cervical cancer and their respective precursor stages in human cervical body samples comprising:

(a)   preparing a sample solution from a human cervical sample;

(b)   detecting the level of at least one relevant marker characteristic for the presence of cervical dysplasia;

(c) detecting the level of at least one normalization marker characteristic for the presence of epithelial cells;

(d) normalizing the levels of the relevant markers to the levels of the normalization markers detected within the sample solution; and

(e) diagnosing cervical dysplasia based on the normalized levels of the relevant markers to the normalization markers.

34. The method according to Claim 33, wherein said at least one relevant marker characteristic for the presence of cervical dysplasia is selected from the group consisting of $p16^{INK4a}$, an HPV associated marker, p14ARF, p19, p21, p27, pRb, p53, cyclin E, cyclin A, cyclin B, MN, her2/neu, mdm-2, bcl-2, EGF-Receptor, MCM2, MCM3, MCM4, MCM5, MCM6, MCM7, CDC2, CDC6, CDC7 protein kinase, CDC14 protein phosphatase, Dbf4, PCNA, Ki67, KiS1, Id1, osteopontine, claudin-1, GRP, renal dipeptidase, and TGFßII receptor.

35. The method according to Claim 33, wherein said at least one normalization marker characteristic for the presence of epithelial cells is selected from the group consisting of gamma-Catenin, Ep-Cam, E-Cadherin, alpha-Catenin, beta-Catenin, Desmoplakin, hKLK13, SCCA, uPA1, Involucrin, CK8, CK18, CK10, CDK13, vimentin, concanavalin A receptor, and lectins.

36. The method according to Claim 33, wherein said method is used in early detection or primary screening tests of cervical lesions.

37. The method according to Claim 33, wherein said human cervical body sample is a swab, a secretion, an aspirate, a lavage, a cell, a tissue, a biopsy or a body fluid.

38. The method according to Claim 33, wherein said epithelial cells are ectocervical or endocervical cells.

39. The method according to Claim 38, wherein a normalization marker indicating the presence of endocervical cells is selected from the group consisting of Ep-Cam, CK8, or CK18.

40. The method according to Claim 38, wherein a normalization marker indicating the presence of endocervical cells is selected from the group consisting of gamma-Catenin, E-Cadherin, alpha-Catenin, beta-Catenin, CK13, p120, or Involucrin.

41. A test kit for diagnosing cervical dyplasia comprising:

(a) at least one reagent for the detection of at least one marker molecule characteristic for cervical dysplasias selected from the group consisting of $p16^{INK4a}$, p14ARF, cyclin E, cyclin A, cyclin B, MN, her2/neu, mdm-2, bcl-2, EGF-Receptor, mcm-2,

mcm-5, claudin-1, markers indicative for Human papilloma virus infection, pRb, and p53; and

(b) at least one reagent for the detection of at least one normalization marker characteristic for the presence or absence of epithelial cells selected from the group consisting of CK8, Ep-Cam, CK13, CK8, CK18, E-Cadherin, alpha-Catenin, beta-Catenin, gamma-Catenin, or Involucrin.

42.   The test kit according to Claim 41, wherein at least one reagent is fixed to a solid phase.

43.   A test kit according to Claim 41, furthermore comprising at least one of the following

components:

(a) at least one marker molecule for carrying out positive control reactions selected from the group consisting of:

(i) relevant marker molecules characteristic for cervical dysplasia,

(ii) normalization marker molecules characteristic for at least one of the

following parameters:

- the presence or absence of columnar epithelial cells;

- the presence or absence of squamous epithelial cells; and

(b) reagents and buffers commonly used for carrying out the detection reaction.

44.   A test kit according to Claim 41, wherein the reagents for detection of marker molecules comprise binding agents specific for said marker molecules and/or nucleic acid probes hybridizing to nucleic acids coding for said marker molecules.

45.   The test kit according to Claim 44, wherein the binding agents are an antibody, a miniantibody, or a peptidomimetic comprising an antigen binding epitope.

46.   The test kit according to Claim 41, wherein the test kit is a diagnostic test kit, an in-vitro diagnostic device, a research kit, or an analytical kit.

47.   A test kit comprising:

(a) a reagent for the detection of p16^{INK4a} ; and

(b) a reagent for the detection of gamma-Catenin.

48.   The test kit according to Claim 47 furthermore comprising a reagent for the detection of Ep-Cam.

49.   The test kit according to Claim 47 furthermore comprising a buffer for sample lysis.

50.　　The test kit according to Claim 47, wherein the reagents for the detection of p16^{INK4a} and gamma-Catenin are fixed to solid phases.

51.　　The test kit according to Claim 47 being an in-vitro diagnostic device.

Drawings:

Figure 1:

Figure 2:

Figure 3:

Diagnosis	PAP IVa PAP IVb PAP IVa PAP IVb	PAP IVa PAP IVb PAP IVa PAP IVb	PAP IVa PAP IVb PAP IVa PAP IVb

Western Blot of

β-actin →   CK10/13 →   CK18 →

p16 →

Patient No.	1 2 3 4	1 2 3 4	1 2 3 4
Signal for p16	+ + - -		
Signal for CK10/13		+ + - -	
Signal for CK 18			+ + - -
Sample adequacy		+ + - -	+ + - -

ELISA Assay for	p16	CK 10/13	CK 18
Patient No.	1 2 3 4	1 2 3 4	1 2 3 4
Result	+ + - -	+ + - -	+ + - -

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   G01N33/574   G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 723 156 A (BEHRING DIAGNOSTICS INC) 24 July 1996 (1996-07-24) claims 1-14	1-27, 33-40
A	WO 99 04238 A (MITOTIX, INC) 28 January 1999 (1999-01-28)	1-27, 33-51
X	claims 1-23	28-32
A	US 0 086 288 A1 (BIRD ET AL) 4 July 2002 (2002-07-04) claims 1-9	1-27, 33-40
A	US 0 039 023 A1 (SCHUBERT) 8 November 2001 (2001-11-08) the whole document	1-51

-/--

X	Further documents are listed in the continuation of box C.		X	Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
18 November 2003	16/12/2003

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Moreno de Vega, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X A	EP 1 217 377 A (BAYER AG) 26 June 2002 (2002-06-26) column 7, line 2-25 -----	28-32 1-27, 33-51

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/50354

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0723156	A	24-07-1996	AU	701544 B2	28-01-1999
			AU	4059795 A	27-06-1996
			CA	2164167 A1	21-06-1996
			EP	0723156 A2	24-07-1996
			JP	8233817 A	13-09-1996
WO 9904238	A	28-01-1999	AU	8403098 A	10-02-1999
			WO	9904238 A2	28-01-1999
US 0086288	A1		NONE		
US 0039023	A1		NONE		
EP 1217377	A	26-06-2002	DE	10063179 A1	20-06-2002
			CA	2365152 A1	18-06-2002
			CN	1360059 A	24-07-2002
			EP	1217377 A2	26-06-2002
			JP	2002296274 A	09-10-2002
			US	2002106685 A1	08-08-2002

专利名称(译)	基于解决方案的诊断方法

公开(公告)号	EP1525476A1	公开(公告)日	2005-04-27
申请号	EP2003766414	申请日	2003-07-31

[标]申请(专利权)人(译)	MTM实验室公司
申请(专利权)人(译)	MTM LABORATORIES AG
当前申请(专利权)人(译)	MTM LABORATORIES AG
[标]发明人	RIDDER RUDIGER REICHERT ANJA TRUNK GEHMACHER MARCUS RUDY WOLFGANG HERKERT MATTHIAS VON KNEBEL DOEBERITZ MAGNUS
发明人	RIDDER, RÜDIGER REICHERT, ANJA TRUNK-GEHMACHER, MARCUS RUDY, WOLFGANG HERKERT, MATTHIAS VON KNEBEL DOEBERITZ, MAGNUS
IPC分类号	G01N33/53 C12Q1/02 C12Q1/04 C12Q1/68 G01N33/50 G01N33/566 G01N33/569 G01N33/574
CPC分类号	G01N33/5076 G01N33/5091 G01N33/574 G01N33/57411 G01N2333/82
优先权	2002017313 2002-08-01 EP
外部链接	Espacenet

摘要(译)

本发明提供了通过在测试样品溶液中进行的基于溶液的生物化学测试程序来改进医学相关病症诊断的方法。本发明提供了一种方法，用于从溶液中获得的分子信息替换测试样品的细胞学和/或组织学数据中包含的基于细胞的形态学信息，其中原始测试样品被溶解，因此能够进行准确和可重复的医学评估。溶解试样的相关诊断。根据本发明的方法包括以下步骤：确定与待诊断病症相关的一种或多种疾病标志物的水平，确定适合于替换与样品的形态方面有关的信息的一种或多种标准化标志物的水平，比较和/或组合疾病和标准化标志物的数据，并评估医学相关病症的诊断。